bZ&iQkesZlh ds fojks/ esa dSfeLV nsaxs Kkiu vEckyk] c`tsanz eYgks=kk%& ns'k ds loksZPp U;k;ky; }kjk vkWuykbu iQkesZlh ds tfj, xzkgdksa rd nokb;ka miyC/ djokuk vc Vs<+h [khj gks x;k gS- iatkc esa ;qok u'ks dh fxjÝr esa uk vk,] blds fy, ihlh, (iatkc dSfeLV ,lksfl,'ku) us iatkc ljdkj o iatkc vkS"kf/ iz'kklu dks Kkiu ds ekè;e ls ekax dh fd vfoy- ac vkWuykbu iQkesZlh }kjk nokb;ka cspus okyksa ds f[kykiQ U;k;ky; ds vkns'kksa dh ikyuk dj jkT; ds ;qokvksa dks u'ks dh xrZ esa tkus ls cpkus esa lkFkZd dne mBk,a- mYys[kuh; gS fd vkWuykbu iQkesZlh ds ekè;e ls feyus okyh nokvksa o vU; lkeku ds ckjs es ckj&ckj ns'kHkj ds dbZ dksuksa ls [kqyklk gks pqdk gS fd vkWuykbu iQkesZlh tgka fcuk iQkekZflLV ds nok O;kikj djrh gS tks MªXl ,aM dkWLesfVd ,DV dh vogsyuk Hkh gS rFkk vkWuykbu ds ekè;e ls MqIyhdsV o fuEu Lrj dh nokb;ka jksfx;ksa rd igqapkus dk dke tkus vutkus vkWuykbu IkQkesZlh }kjk fd;k tk jgk gS- vRk% iatkc esa bl izdkj ds fdlh Hkh izfr"Bku dh vfoyac iw.kZ :i ls can fd;k tk,- chlh, ds izns'k vè;{k lqjsanz nqXxy o jkT; egklfpo th,l pkoyk ds vuqlkj 'kh?kz gh ftyk Lrj ij vkS"kf/ iz'kklu o jkT; ljdkj ds iz'kklfud vf/dkfj;ksa dks Kkiu ds ekè;e ls ,d lw=kh dk;ZØe pyk;k tk,xk- jkT; ds ;qok vkWuykbu iQkesZlh ds ekè;e ls u'ks dh nokbZ dh pisV esa uk vk,a vkSj jksxh tks dqN NwV ds ykyp esa vkWuykbu iQkWekZ ls fuEu Lrj dh nokb;ka [kjhn viuh chekfj;ksa dks vkSj vf/d uk c<+k ik,- nqXxy us dgk fd jkT; ds gj 'kgj dLCks xkao Lrj ij fjVsy o gksylsy dh nokvksa ds foØ; gsrq iatkc dsfeLV ,lksfl,'ku ds lnL; vius O;kikfjd izfr"Bku [kqys gq, gSa tks vketu dh t:jrksa vuqlkj nok dks nok ds :i es jksfx;ksa rd igqapkus dk dk;Z dj jgs gSa- ;fn dksbZ nok O;olkbZ nok dks u'ks ds :i esa fdlh dks Hkh miyC/ djokrk gS- jkT; laxBu ftyk laxBu LFkkuh; laxBu fdlh Hkh Lrj ij ml nok O;olkbZ dks laj{k.k ugha nsrk] mYVk ljdkj o vkS"kf/ iz'kklu ds lkFk da/s ls da/k feykdj u'ks dks tM+ ls feVkus ds fy, opuc} gS- Good Relation Good NeverBreak
C ipla Founda tion Awa r ds Sc hola r s hips To Stude nts Fr om Goa C olle ge Of Pha r m a c y Goa :- In co n ti n u a n ce o f i ts e ffo rts to p ro mo te q u a l i ty e d u ca ti o n , Cip l a F o u n d atio n , Ph.:- 0 2 0 -2 5 2 3 11 3 0 th e so ci a l re sp o n si b i l i ty a rm o f C i p l a L td , h a s pa rtn e re d w i th th e Go a C o l l e g e o f Ph a rma cy fo r th e fi rst ti me to p ro vi d e sch o l a rsh i ps to d e se rvi n g stu d e n ts from fi n a n ci a l l y d i sa d va n ta g e d b a ckg ro u n d s. Th i s pa rtn e rsh i p w i l l h el p se l e cte d stu d e n ts w i th fi n a n ci a l su p p o rt to w a rd s th e i r fe e s for va ri o u s co u rse s su ch a s, D i p l o ma i n Ph a rma cy, Ba ch e l o r o f Ph a rma cy a n d Ma ste r o f Ph a rma cy. Th e Ch i e f Gu e st, D r. G. K. R a o , Pri n ci pa l , Go a C o l l e g e o f Ph a rma cy, fe l i ci ta te d th e stu d e n ts w i th ce rti fi ca te s a n d fi n a n ci a l g ra ti fi ca ti o n o n 5 th D e ce mb e r 2 0 1 9 i n th e co l l eg e p re mi se s i n Pa n a j i . Th e e ve n t w a s a tte n d e d b y se n i o r o ffi ci a l s fro m C i p l a L td Go a a n d C i pl a Fo u n d a ti o n . Th e co l l a b o ra ti o n a i ms to e mp o w e r stu d e n ts fro m l e sse r p ri vi l e g e d fa mi l i e s b y h e l p i n g th e m co mp l e te th e i r e d u ca ti o n a n d b e re a d y fo r e mp l o yme n t o p p o rtu n i ti e s. C h i e f Gu e st, D r G. K. R a o , Pri n ci pa l , Go a C o l l e g e o f Ph a rma cy, sa i d , “Ou r fo cu s h a s b e e n to p ro vi d e th e n e xt g e n e ra ti o n w i th a p t ski l l s, kn o w l e d g e a n d a ca d e mi c e xce l l e n ce , so th e y ca n ta ke u p ro le s a n d ru n th e co mmu n i - ty p h a rma ci e s. Th i s pa rtn e rsh i p i s a p ro mi si n g ste p to w a rd s a ch i e vi n g th i s g o a l s.” C o mme n ti n g o n th e l a u n ch , Ms. R u ma n a H a mi e d , Ma n a g i n g Tru ste e, C i p l a Fo u n d a ti o n , sa i d , “We a re d e l i g h te d to co me to g e th e r w i th a n i n sti tu tio n o f re p u te l i ke th e Go a C o l l e g e o f Ph a rma cy to su p p o rt th e a sp i ra ti o n s a n d a mb i ti o n s o f stu d e n ts. It i s i mp e ra ti ve to n u rtu re a g e n e ra ti o n o f e d u ca te d , i n fo rme d a n d ski l l e d yo u th w h o a re e mp o w e re d to cre a te a p ro d u c- ti ve fu tu re .” As pa rt o f i ts fo cu s o n i mp ro vi n g e d u ca ti o n o u tco me s, C i p l a Fo u n d a ti o n su p p o rts u n i q u e d e ve l o p me n ta l i n i ti a ti ve s th ro u g h i ts C SR i n te rve n ti on s a n d w o rks cl o se l y w i th l o ca l ¶vxj vki lksprs gSa fd Kku ikuk egaxk gS rks] vKkuh cudj ns[kks¸ co mmu n i ti e s a n d th e g o ve rn me n t th ro u g h co l l a b o ra ti ve pa rtn e rsh i ps. ¶D;k vkidks Kku gS fd izse dk nsg ls dksbZ lEcU/ ugha\¸ {kf.kdk iqu%LFkkiu ,d tkrk] nwtk vkrk- lkjk lalkj] py ikrk- nkf;Ro ftEesnkfj;ka] Lo;a laHkkyks- nwljksa ds Åij] dHkh uk Vkyks- Hkjkslk gj ckr ij] 'kd er djks- eu esa dgh] FkksM+k fo'okl /jks- ;qojkt flag N% ckWy] N% NDds- ;qojkt gSa] /qu ds iDds- vktdy ykt fygkt laLdkj] lc
3 o"kZ rd ?kj cSBs ;g lekpkj i=k i<+us ds fy;s gekjs iatkc uS'kuy cSad ds [kkrk la[;k 1824002100120081] IFSC Code - PUNB0182400 tks fd eSMhdy niZ.k ds uke ls gS] esa :ú 250@& tek dj viuk iwjk irk gekjs iQksu uaú& 09410434811 ij SMS dj nsaA {kf.kdk n`f"V vk¡[kksa dh] vfHkO;fDr- fcuk cksys] eu dh 'kfDr- lkeatL; thou esa] larqyu rks pkfg,- iwjh vk;q] lq[kh th ikbZ,- futh igys Lo;a] dks lq/kjks- fiQj nqfu;k] dks lokjks- lkFk feydj] py ik,- liQy] gks tk,- fur vkSlr dekvks] ij jkst dekvks- vafre {k.k rd] lEeku dks ikvks- vk/kj vk;q gj iy] u;k jax fn[kkrh- >qfjZ;ksa dk vkuk] vuqHko dks n'kkZrh- ikVhZ dqN Msªl] BaM dks Hkqykrs- xehZ dk ,glkl fnykrs- dqN flj ds rqyuk] pkan ls djrs gSa- ogk¡ iQly ugha gS] ;gk¡ cky ugha gS- p;u ru chekj] nok ls lq/kjksa- eu chekj] Lo;a dks lq/kjksa- foijhr vgadkj ikl] rks bZ'oj nwj- bZ 'oj ikl] rks vagdkj nwj- bPNk tkrs&tkrs] lc Hkyk dgsa- nqvk ns ikbZ,] ;gh cl pkfg,- & MkWñ ujsUnz ukFk ykgk Xokfy;j (e-iz-) eksñ 09753698240- dksgjs esa xkM+h pykrs è;ku j[ks nq?kZVuk ls cps] thou cpk;s mRrj Hkkjr esa BaM ds lkFk&lkFk dksgjk Hkh c<+ x;k gS- /qa/ ds dkj.k foftfcfyVh dkiQh de gks x;h gS- ;gh dkj.k gS fd gj jkst lM+dksa ij nq?kZVuk,a gks jgh gS- bu gknlksa esa vHkh rd dbZ ekSrsa gks pqdh gS- dksgjs ds chp lM+d ij lqjf{kr liQj ds fy, pkyd dk tkx:d gksuk t:jh gS- T;knkrj nq?kZVuk,a blfy, gksrh gS fd yksx dksgjk gksus ds ckotwn viuh xkM+h dh jÝrkj /hjs ugha djrs- mUgksus dgk fd ;s è;ku j[kuk t:jh gS ftruh vkidh xkM+h dh LihM gS] mruh gh nq?kZVuk dh laHkkouk c<+ tkrh gS- dSls djsa cpko\ - foftfcfyVh csgn [kjkc gksus ij lM+d ij dyj dh xkbMykbu dks iQkWyks djsa- &iSny] lkbfdy vkSj nks ifg;k ij pyus okys laHko gks rks CySd ;k MkdZ dyj ds diM+s u igusa- &iSny lkbZfdy vkSj nks ifg;k pykus okys jsfM;e tSdsV igusa- & okguksa ij [kklrkSj ls lkbZfdy ij jsfM;e Vsi dk bLrseky djsa tks yksx LdwVj ;k ckbZd ij tkrs gS oks gsyesV ij Hkh jsfM;e Vsi dk bLrseky djsa- & dksgjs esa xkM+h dks lM+d ij ikdZ u djsa] vxj FkksM+h nsj ds fy, lM+d ij xkM+h jksd jgs gSa rks pkjks bafMdsVj vkWu j[ksa- vuqHkoh MkDVjksa dk ijke'kZ ukS,Mk fLFkr lqij Lis'kfyVh vLirky ;FkkFkZ eksñ 8130206637 ds MkWñ uhjt pkS/jh cqyUn'kgj fLFkr ve;s'k gkWfLiVy esa viuh lsok,a nsaxs- gsYiykbZu uañ 8800447777- U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW TO SNDA FOR BRAFTOVI® (ENCORAFENIB) IN COMBINA- TION WITH ERBITUX® (CETUXIMAB) (BRAFTOVI DOUBLET) FOR THE TREATMENT OF BRAFV600E-MUTANT METASTATIC COLORECTAL CANCER AFTER PRIOR THERAPY Pfizer Inc. Mob:- 09039483991, 09997456338, 09887245322 announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to the Company’s supplemen- tal New Drug Application (sNDA) for BRAFTOVI® (encorafenib) in combination with ERBITUX® (cetuximab) (BRAFTOVI Doublet) based on results from the Phase 3 BEACON CRC trial, which evaluated the efficacy and safety of BRAFTOVI in combination with ERBITUX with or without MEK- TOVI® (binimetinib) in patients with advanced BRAFV600E-mutant metastatic colorectal cancer (mCRC), following one or two lines of therapy. As published in The New England Journal of Medicine (NEJM), results from the BEACON CRC trial showed improvements in overall survival (OS) and objective response rates (ORR) for both the BRAFTOVI Doublet and BRAFTOVI Triplet (BRAFTOVI, MEKTOVI and ERBITUX) combination, compared to ERBITUX plus irinotecan- containing regimens (Control).1 In descriptive analyses comparing the Doublet and Triplet arms, the results showed compara- ble efficacy between the Doublet and Triplet in the overall population. The BRAFTOVI Triplet and Doublet showed no unex- pected toxicities. “The FDA’s acceptance of our application for the BRAFTOVI Doublet is highly encouraging news for patients with mCRC harboring a BRAFV600E mutation,” said Chris Boshoff, M.D., Ph.D., Chief Development Officer, Oncology, Pfizer Global Product Development. “Currently, there are no FDA-approved treatments specifically for patients with BRAF-mutant mCRC who have received prior treatment. If approved, the BRAFTOVI Doublet would become the first targeted regimen for this patient population, who typically have a poor prognosis. We also look forward to continuing to explore this targeted Doublet regimen with or without MEKTOVI in earlier lines of BRAF-mutant mCRC, including in the ongoing, Phase 2 ANCHOR study in previously untreated patients.” The FDA grants Priority Review to medicines that may offer significant advances in treatment or may provide a treatment where no adequate therapy exists. The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is in April 2020. On November 2, 2019, the European Medicines Agency (EMA) also started the review procedure for Pierre Fabre’s Type II variation applications based on the BEACON CRC trial. About Colorectal Cancer Worldwide, colorectal cancer is the third most common type of cancer in men and the second most common in women, with approximately 1.8 million new diagnoses in 2018.2,3 In the U.S. alone, an estimated 140,250 patients were diagnosed with cancer of the colon or rectum in 2018, and approximately 50,000 are estimated to die of their disease each year.4 BRAF muta- tions are estimated to occur in up to 15% of patients with mCRC and represent a poor prognosis for these patients.5,6,7,8,9,10 The V600 mutation is the most common BRAF mutation and the risk of mortality in CRC patients with the BRAFV600E muta- tion is more than two times higher than for those with wild-type BRAF.7,8 BRAFV600E-mutant mCRC is an area of high unmet need as there are currently no approved therapies specifically indicated for patients with BRAF-mutant mCRC.11,12, 13 About BEACON CRC BEACON CRC is a randomized, open-label, global trial evaluating the efficacy and safety of BRAFTOVI, MEK- TOVI and ERBITUX in patients with BRAFV600E-mutant mCRC whose disease has progressed after one or two prior regi- mens. The randomized portion of the BEACON CRC trial is designed to assess the efficacy and safety of BRAFTOVI in com- bination with ERBITUX with or without MEKTOVI compared to ERBITUX and irinotecan-based therapy. 665 patients were ran- domized 1:1:1 to receive the Triplet combination, the Doublet combination (BRAFTOVI and ERBITUX) or the control arm (irinotecan-based therapy and ERBITUX). The study was amended to include an interim analysis of endpoints including ORR. The primary overall survival endpoint is a comparison of the Triplet combination to the control arm. Secondary endpoints address efficacy of the Doublet combination compared to the control arm, and the Triplet combination compared to the dou- blet therapy. Other secondary endpoints include progression-free survival, duration of response, safety and tolerability. The trial is being conducted at over 200 investigational sites in North America, South America, Europe and the Asia Pacific region. The BEACON CRC trial is being conducted with support from Ono Pharmaceutical Co. Ltd., Pierre Fabre and Merck KGaA, Darmstadt, Germany (support is for sites outside of North America). About BRAFTOVI + MEKTOVI BRAFTOVI is an oral small molecule BRAF kinase inhibitor and MEKTOVI is an oral small mol- ecule MEK inhibitor which target key enzymes in the MAPK signal- ing pathway (RAS-RAF-MEK-ERK). Inappropriate activation of pro- teins in this pathway has been shown to occur in many cancers including melanoma and colorectal cancer. In the U.S., BRAFTOVI + MEKTOVI are approved for the treatment of unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation, as detected by an FDA-approved test. BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma. In Europe, the combination is approved for adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation, as detected by a validated test. In Japan, the combination is approved for unre- sectable melanoma with a BRAF mutation. Pfizer has exclusive rights to BRAFTOVI and MEKTOVI in the U.S. and Canada. Ono Pharmaceutical Co. Ltd. has exclusive rights to commercialize both products in Japan and South Korea, Medison has exclusive rights to commercialize both products in Israel and Pierre Fabre has exclu- sive rights to commercialize both products in all other countries, including Europe, Latin America and Asia (excluding Japan and South Korea). Indications and Usage BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) are kinase inhibitors indicat- ed for use in combination for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation as detected by an FDA-approved test. Limitations of Use: BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma. BRAFTOVI + MEKTOVI Important Safety Information The information below applies to the safe- ty of the combination of BRAFTOVI and MEKTOVI unless otherwise noted. See full Prescribing Information for BRAFTOVI and for MEKTOVI for dose modifications for adverse reactions. WARNINGS AND PRECAUTIONS New Primary Malignancies, cutaneous and non-cutaneous malignancies can occur. In the COLUMBUS trial, cutaneous squamous cell carcinoma (cuSCC), including keratoacanthoma (KA), occurred in 2.6% and basal cell carcinoma occurred in 1.6% of patients. Median time to first occurrence of cuSCC/KA was 5.8 months. Perform dermatolog- ic evaluations prior to initiating treatment, every 2 months during treatment, and for up to 6 months following discontinuation of treatment. Manage suspicious skin lesions with excision and dermatopathologic evaluation. Dose modification is not recommended for new primary cutaneous malignancies. Based on its mechanism of action, BRAFTOVI may promote malignancies associated with activation of RAS through mutation or other mechanisms. Monitor patients receiving BRAFTOVI for signs and symptoms of non-cutaneous malignancies. Discontinue BRAFTOVI for RAS mutation-positive non-cutaneous malignancies. Tumor Promotion in BRAF Wild-Type Tumors: In vitro experiments have demonstrated paradoxical activation of MAP- kinase signaling and increased cell proliferation in BRAF wild-type cells exposed to BRAF inhibitors. Confirm evidence of BRAF V600E or V600K mutation prior to initiating BRAFTOVI. Cardiomyopathy, manifesting as left ventricular dysfunction associated with symptomatic or asymptomatic decreases in ejection fraction, has been reported in patients. In the COLUMBUS trial, evidence of cardiomyopathy occurred in 7% and Grade 3 left ventricular dysfunction occurred in 1.6% of patients. The median time to first occurrence of left ventricular dysfunction (any grade) was 3.6 months. Cardiomyopathy resolved in 87% of patients. Assess LVEF by echocardiogram or MUGA scan prior to initiating treatment, 1 month after initiating treatment, and then every 2 to 3 months during treatment. The safety has not been established in patients with a baseline ejection fraction that is either below 50% or below the institutional lower limit of normal (LLN). Patients with cardiovascular risk factors should be monitored closely. Venous Thromboembolism (VTE): In the COLUMBUS trial, VTE occurred in 6% of patients, including 3.1% of patients who developed pulmonary embolism. Hemorrhage: In the COLUMBUS trial, hemorrhage occurred in 19% of patients and ≥ Grade 3 hemorrhage occurred in 3.2% of patients. Fatal intracra- nial hemorrhage in the setting of new or progressive brain metastases occurred in 1.6% of patients. The most frequent hemorrhagic events were gastrointestinal, including rectal hemorrhage (4.2%), hematochezia (3.1%), and hemorrhoidal hemorrhage (1%). Ocular Toxicities: In the COLUMBUS trial, serous retinopathy occurred in 20% of patients; 8% were retinal detachment and 6% were macular edema. Symptomatic serous retinopathy occurred in 8% of patients with no cases of blindness. The median time to onset of the first event of serous retinopathy (all grades) was 1.2 months. RVO is a known class-related adverse reaction of MEK inhibitors and may occur in patients treated with MEKTOVI in combination with encorafenib. In patients with BRAF mutation-positive melanoma across multiple clinical trials, 0.1% of patients experienced retinal vein occlusion (RVO). The safety of MEKTOVI has not been established in patients with a history of RVO or current risk factors for RVO including uncontrolled glaucoma or a history of hyperviscosity or hypercoagulability syndromes. Perform ophthalmological evaluation for patient- reported acute vision loss or other visual disturbance within 24 hours. Permanently discontinue MEKTOVI in patients with documented RVO. In COLUMBUS, uveitis, including iritis and irido- cyclitis was reported in 4% of patients treated with MEKTOVI in combination with BRAFTOVI. Assess for visual symptoms at each visit. Perform an ophthalmological evaluation at regular inter- vals and for new or worsening visual disturbances, and to follow new or persistent ophthalmologic findings. Interstitial Lung Disease (ILD): ILD, including pneumonitis occurred in 0.3% of patients with BRAF mutation-positive melanoma across multiple clinical trials. Assess new or progressive unexplained pulmonary symptoms or findings for possible ILD. Hepatotoxicity: In the COLUMBUS trial, the incidence of Grade 3 or 4 increases in liver function laboratory tests was 6% for alanine aminotransferase (ALT), 2.6% for aspartate aminotransferase (AST), and 0.5% for alkaline phosphatase. No patient experienced Grade 3 or 4 serum bilirubin elevation. Monitor liver laboratory tests before initiation of MEKTOVI, monthly during treatment, and as clinically indicated. Rhabdomyolysis: In the COLUMBUS trial, elevation of laboratory values of serum CPK occurred in 58% of patients. Rhabdomyolysis was reported in 0.1% of patients with BRAF mutation-positive melanoma receiving MEKTOVI with encorafenib across multiple clinical trials. Monitor CPK and creatinine levels prior to initiating MEKTOVI, periodically during treat- ment, and as clinically indicated. QTc Prolongation: BRAFTOVI is associated with dose-dependent QTc interval prolongation in some patients. In the COLUMBUS trial, an increase in QTcF to > 500 ms was measured in 0.5% (1/192) of patients. Monitor patients who already have or who are at significant risk of developing QTc prolongation, including patients with known long QT syndromes, clinically significant bradyarrhythmias, severe or uncontrolled heart failure and those taking other medicinal products associated with QT prolongation. Correct hypokalemia and hypomagnesemia prior to and during BRAFTOVI administration. Withhold, reduce dose, or permanently discontinue for QTc > 500 ms. Embryo-Fetal Toxicity: BRAFTOVI or MEKTOVI can cause fetal harm when administered to pregnant women. BRAFTOVI can render hormonal contraceptives ineffective. Nonhormonal contraceptives should be used during treatment and for at least 30 days after the final dose for patients taking BRAFTOVI + MEKTOVI. Risks Associated with BRAFTOVI as a Single Agent: There is an increased risk of certain adverse reactions compared to when BRAFTOVI is used in combination with MEKTOVI. Grades 3 or 4 dermatologic reactions occurred in 21% of BRAFTOVI single agent compared to 2% in patients treated with BRAFTOVI in combination with MEKTOVI. If MEKTOVI is temporarily interrupted or permanently discontinued, reduce the dose of BRAFTOVI as recommended. dksbZ vad ugha feyk rks ,l-,e-,l- dj nsa iQkekZ U;wt dk ;g vad vkids gkFk esa gS- iQkekZ U;wt dk tc ls izdk'ku izkjEHk gqvk] rc ls bldk dksbZ Hkh vad :dk ugha- iQkekZ U;wt ds izR;sd xzkgd (lClØkbcj) dk uke] irk dEI;wVjkbTM gS- fMLiSp ds le; dEI;wVj vkVkseSfVd
3 o"kZ rd ?kj cSBs ;g lekpkj i=k i<+us ds fy;s gekjs iatkc uS'kuy cSad ds [kkrk la[;k 1824002100120081] IFSC Code - PUNB0182400 tks fd eSMhdy niZ.k ds uke ls gS] esa :ú 250@& tek dj viuk iwjk irk gekjs iQksu uaú& 09410434811 ij SMS dj nsaA Product List OM BIOTEC ENZOM-DR (Trypsin 48mg + Bromelain 90 + Rutoside 100mg + Diclofenac Potassium 50mg) l ENZOM-DR FORTE (Trypsin INJECTABLES:-lBYFE-100 (Iron sucrose - 100mg) l 96mg + Bromelain 180mg + Rutoside 200mg) l FASZIDE-M COBALOM (Mecobalamin 500 mcg) l COBALOM-FORTE (Vit.B1 100mg,B6 100mg,D-Panthenol 50mg,Mecobalamin (Gliclazide 80mg, Metformin HCL 500mg, SR) l FEXOKIND-120 (Fexofenadine 120mg) l FEXOKIND-180(Fexofenadine 180mg) 1000mcg, Nicotinamide 100mg) l DEC-OMBOLIN-25 l FLUCOM-150 (Fluconazole 150 mg) l FLUCOM 150 (Nandrolone Decanoate 25mg B.P) l DEC-OMBOLIN-50 (Fluconazole 150 mg) l FLUCOM-200 (Fluconazole 200mg) l (Nandrolone Decanoate 50mg B.P) l DEXOM (Dexamethasone FLUCOM-400 (Fluconazole 400mg) l FOLIOSIL (Folic Acid 5mg) 4mg) DIC-75 (Diclofenac Sodium IP 75 mg / 1ml) l JINTUM l GRIPCOLD-PLUS (Cetrizine 5mg, Para325mg,Phenylephrine TZB-281.25 (Ceftazidime 250mg, Tazobactum 31.25mg) l OMCILLIN TZB-4.5 (Piperacillin 4gm + Tazobactum 500mg WFI HCI 5mg) l HEAMGROW-XT (Ferrous Ascorbate 100mg, Folic Acid 1.5mg) l HYDROSIN-25 (Hydroxyzine 25mg) l JINCOLD IN TRAY) l OMETHER (Alfa Beta Arteether 150mg) l OMICORT (Para 325mg,CPM 2mg,Ceffeine 25mg,Phenylephrine HCI 5mg) (Triamcinolone Acetonide 40mg) l OMIKIN-100 (Amikacin I.P. l JFLO-200 (B) (Ofloxacin 200mg) JFLO-200 (A/A) (Ofloxacin 100mg) l OMIKIN-500 (Amikacin I.P. 500mg) l OZINEX-1gm (Cefoperazone Sodi. 500mg, sulbac- 200mg) l JFLO-400 (Ofloxacin 400mg) l JFLOCEF-400 (Ofloxacin 200mg,Cefixime tam sodi 500mg, WFI) l OZINEX- 1.5gm (Cefoperazone Sodium 200mg.) l JFLO-OZ (Ofloxacin 200mg + 1000mg, sulbactam sodium 500mg) l PROSAFE DEPOT-250 Ornidazole 500 mg) l (Hydroxyprogesterone Caproate KETAKROL-DT (Ketorolac Tromethamine DT 10mg 250mg IP) l PROSAFE DEPOT-500 (Hydroxyprogesterone Caproate (Mouth Disolving Tab.) l 500mg IP) PFD-40 (Pantoprazole MESPAS (Mefenamic Acid 250mg, Dicyclomine HCl 40mg) l RENECEF-SB-375 (Ceftriaxone 250mg.,Sulbactum 10mg) l MESPAS-DRT (Mefenamic Acid 250mg, 125mg.WFI IN TRAY) l RENECEF-SB- 1500 (Ceftriaxone 1gm.,Sulbactum Drotaverine 80mg) l MES- 500mg. WFI IN TRAY) TRIAXOM-250 PAS-FORTE (Mefanamic (Ceftriaxone Sodium USP 250mg WFI) Acid 250mg, Paracetamol 325mg) l NIMUBOL l TRIAXOM-500 (Ceftriaxone Sodium (Nimesulide 100mg USP 500mg WFI) l TRIAXOM-1000 (Ceftriaxone Sodium USP 1gm. WFI) (10X50) l NIMUBOL- CAPSULES:- BYFE (Carbonyl Iron 50mg, Zinc Sulphate PLUS (Nimesulide 100mg, Paracetamol 325mg) l OMEXTIL-500 (Cefuroxime Axetil eq. to Cefuroxime 500mg) l OMFLOX-250 61.8mg, Folic Acid 0.5mg) l COBALOM-FORTE (Mecobalamin 1500mcg, Folic Acid 1.5mg, Vitamin B1-10mg, (Levofloaxacin 250mg) l OMFLOX-500 (Levofloaxacin 500mg) l OMFLOX-OZ (Levofloaxacin 250mg, Ornidazole 500mg) l OMI- Vitamin B6-3mg, Alpha Lipoic Acid 100mg) l EURONERV-PG (Pregabalin 75mg + Methylcobalamin 750mcg) ETRICOM-100 GRA-100 (Sildenafil Citrate 100mg (RED TABLET) OMOX-250 DT (Amoxycillin 250mg (Dispersible Tablet) l OMOX-CLV 625 (Itraconazole 100mg) l ETRICOM-200 (Itraconazole 200mg) l (Amoxycillin 500mg, Potassium Clavulanate 125mg) l OMOX- JINCLOX-LB (Amoxycillin 250mg + Cloxacillin 250mg + L.A.B.) l CLV 625 (Amoxycillin 500mg, Potassium Clavulanate 125mg) l JINCLOX-LB (Amoxycillin 250mg + Cloxacillin 250mg + L.A.B.) l JINFOL (Carbonyl Iron 100mg, vitamin B 12 15mcg, Zinc ONROCK-MD (Ondansetron 4mg (Mouth Dissolving Tablet) l Sulfonyl Methane 250 mg.) l DIVINERV-OD (Methyl Cobalamin PFD-40 (Pantoprazole 40mg) l PFD-PLUS (Pantoprazole 40mg, Sulphate 61.80mg, Vitamin C 75mg, Folic Acid 1.5mg) l 1500 mcg + Alpha Lipoic Acid 100 mg + Inositol 100 mg + Vit B + LYCOFEE-RED (Lycopene 10% 2000mcg, Vitamin A Vit B6 + Folic acid & Chromium) l DIVINERV-GB concentrate 2500 IU Ascorbic Acid (Vitamin C) 50mg (Methylcobalamin–500 mcg + Gabapentin-300 mg) l Vitamin E acetate 10 IU Zinc Sulph. Monohydrate DOT-250DT (Amoxycillin 250 mg.+Lactic Acid Bacillus l 27.45mg,Selenium Dioxide 70mcg) l OMOCID 60 million spores) DIVINASE FORTE (Trypsin- l (Omeprazole 20mg) l OMOCID-PLUS (Omeprazole Chymotrypsin 1 lac A.U) DIVINASE- RB (Trypsin 48 20mg, Domperidone 10mg) l OMOX-500 (Amoxycillin mg + Bromelain 90 mg + Rutoside Trihydrate 100 mg) l 500mg) l PFD-SR (Pantoprazole 40mg, Domperidone DOTCLAV- 625 (Amoxycillin 500 mg + Clavulanic l 30mg, (Sustained Release) l PROFIT PLUS (Protein acid 125 mg) FLAMIN-MR (Ibuprofen 400 mg + l With Multivitamin & Mineral Capsule) l RABEPROM-D Paracetamol 325 mg. + Chlorzoxasone 250 mg.) (Rabeprazole 20mg, Domperidone 30mg.(SR)) l FLAMOL-D (Diclofenac Potassium 50 mg + RABEPROM-IT (Rabeprazole Sodium 20mg, Itopride Paracetamol 325 mg) l FLUWELL (Flunarizine 10 mg l l Hcl 150mg (SR)) l RABEPROM-LSR (Rabeprazole ) FEBUQUEST-40 (Febuxostat 40 mg) FALQUEST 20mg, Levosulpiride 75mg)SOFT GEL CAPSULE:- (Artemether-80 mg +Lumefantrine-480 mg) l AN-Q10 FORTE (Co-Enzyme Q 10, L-Carnitine GABAQUEST-NT (Gabapentin-300 mg + Nortryptilene Lycopene, Multivitamin with DHA, L-Arginine & green 10 mg) l LEVOCLIC-PLUS (Levocetrizine 5 mg + Tea Extract Soft Gel) l D3-MIN (Cholecalciferol 60000 Ambroxol 30 mg + Phenylephrine 5 mg + PCM 325 mg) l l I.U.) l EV-NUTRA 400 (Vitamin E, Wheat Germ Oil & LEVOCLIC (Levocetirizine 5 mg) LEVOCLIC-M l Omega 3 Fatty Acid) l FM-GOLD (Vitamins, Minerals, (Levocetirizine 5 mg + Montelukast 10 mg) LEVO- l Ginseng with L-Arginine) l JINPLEX-GM QUEST-500 (Levofloxacin 500 mg) MOFLO-200 (Multivitamins, Minerals with Ginseng & (Ofloxacin 200 mg.) l MOFLO-OD (Ofloxacin 400 mg) l Methylcobalamin) l OM-4G-FORTE (Omega 3 fatty MOFLO-OZ (Ofloxacin 200 mg + Ornidazole 500 mg) l l acid, Tea extracts with Vita. Extract Combination) l PUREST (Cetirizine 10 mg.) QUPRAZ 40 PEARL EYE POWER (Vitamin A, Vitamin C, Vitamin E, (Pantoprazole 40 mg) l QUPRAZ-DM (Pantoprazole l Selenium, Copper & Zinc) l PHYT-VIT (Multivitamins, 40 mg.+ Domperidone 10 mg.) QUPOD-200DT l Minerals & Antioxidant) l PROSAFE DEPOT-200 (Cefpodoxime 200 mg) QUPOD-CV (Cefpodoxime l (Natural Progesterone Capsule 200mg) l SHELLVIT- 200 mg + Clavulanic acid 125 mg.) QURON-XT CZ (Calcitriol 0.25mcg, Calcium Carbonate 500mg, (Ferrous Ascorbate 100 mg + Folic Acid 1.5 mg + Zinc Domperidone 10mg) l RABEPROM-20 (Rabeprazole 20mg) l l l Zinc 7.5mg) l SHELLVIT K2-7 (Calcitriol 0.25mcg, Calcium 22.5 mg) QUIZ-500 (Azithromycin-500 mg) SPOROCEF- Carbonate 625mg, Vit. K2-7 45mcg)TABLETS:-ACELOM (B) RENECEF-CLV ("Cefpodoxime 200mg, Potassium Clavulanate 100DT (Cefixime 100 mg dispersible tablets ) l SPOROCEF- 125 mg") l RENECEF-O100 DT (Cefpodoxime Proxetil 100mg (Aceclofenac 100mg) l ACELOM-MR (Aceclo 100mg, Para 200DT (Cefixime 200 mg + Lactic Acid Bacillus 60 Million Spores DT) l RENECEF-O 200 (Cefpodoxime Proxetil 200mg) l SHEL- l 325mg Chlorzoxazone 250mg) l ACELOM-P (B) (Aceclofenac dispersible tablets) SPOROCEF-CV (Cefixime 200 mg + LVIT-D (Elemental Calcium 500mg, Vitamin D3 IP 250 IU) l l 100mg, Paracetamol 325mg) l ACELOM-P (A/A) (Aceclofenac Clavulanic acid 125 mg.) SPOROCEF-O (Cefixime 200 mg + SHELLVIT-D (Elemental Calcium 500mg, Vitamin D3 IP 250 IU) l 100mg, Paracetamol 325mg) l ACELOM-SP (Aceclo 100mg, Ofloxacin 200 mg) SPEEDON-P (Aceclofenac 100 mg + TERBIROM-250 (Terbinafine 250mg) l TRILERGIC-AM Para 325mg, Serratio. 15mg) l ACELOM-TH (Aceclofenac Paracetamol 325 mg) l SPEEDON-SP (Aceclofenac 100 mg + (Acebrophylline 200mg, Montelukast 10mg, Levocetirizine 5mg) l 100mg, Thiocolchicoside 4mg) l ADDCORT-6 (Deflazacort 6mg) PCM 325 mg + Serratiopeptidase 15 mg) l SPEEDON-MR UDINEX-300 (Ursodeoxycholic Acid 300mg) l VERNAZE-8 l ADDSONE-4 (Methylprednisolone 4mg) l ADDSONE-16 (Aceclofenac 100 mg + PCM 325 mg + Chlorzoxazone 250 mg) (Betahistine 8mg) l WILZIDE-M1 (Glimepiride 1mg, Metformin (Methylprednisolone 16mg) l ALBOM-400 (Albendazole 400mg) l SPEEDON – TH4 (Aceclofenac 100 mg + Thiocolchicoside 4 Hydrochloride 500mg,) l WILZIDE-M2 (Glimepiride 2mg, l ALBOM-PLUS (Albendazole 400mg + Ivermectin 6mg) APPE- mg) l SPEEDY-SD (Diclofenac Potassium 50 mg Metformin Hydrochloride 500mg,) DRY SYRUPS:-CEFCEM TIDIN (Cyproheptadine 4mg.) l ATENOM-AM (Amlodepine 5mg, +Serratiopeptidase 10mg) l SUZIN-500 (Ciprofloxacin 500 mg.) (Cefixime 50mg) (WITH WATER) l CEFCEM-100 (Cefixime Atenolol 50mg) ATENOM-AM (Amlodepine 5mg, Atenolol 50mg) l SUZIN-TZ (Ciprofloxacin 500 mg + Tinidazole 600 mg) l 100mg (GLASS BOTTLE + WITH WATER )l JFLOCEF l AZITHOM-250 (Azithromycin USP 250mg) l AZITHOM-500 TRUSTIN PRO (Etizolam 0.5 mg + Propranolol HCL 20 mg.) l (Cefixime 50mg + Ofloxacin 50mg) l OMOX (Amoxycillin 125mg) (Azithromycin USP 500mg) l CEFCEM-100 DT (Cefixime 100 mg VERTIPRO (Paracetamol 500 mg + Prochlorperazine) l l OMOX-CLV (Amoxycillin 200mg,Clav. Acid 28.5mg, (WITH (Dispersible Tablet) l CEFCEM-200 (DT) (Cefixime 200 mg ZOSTAR-20 (Rabeprazole 20 mg) CAPSULES:- DOT-250 WATER) l RENECEF-O (Cefpodoxime Proxetil 50mg (WITH (Dispersible Tablet)) l CEFCEM-200 (LB) (Cefixime 200mg with (Amoxycillin 250 mg. + Lactic Acid Bacillus 60 million spores) l WATER)EYE / EAR DROPS:- CIPROM-D (Cipro 0.3% w/v, Dexa Lactic Acid Bacillus 60 million spores) l CEFCEM-CLV (Cefixime DOT-500 (Amoxycillin 500 mg. + Lactic Acid Bacillus 60 million 0.01% w/v, Benzalkonium Cl. 0.02% w/v) l JFLO-D (Ofloxa 0.3%, 200mg, Potassium Clavulanate 125mg) l CEFCEM-OZ (Cefixime spores) l GLIDANT (Multivitamins + Multiminerals + Anti-oxi- w/v, Dexa 0.01% w/v, Benzalkonium Cl. 0.02% w/v) l PEARL 200mg, Ornidazole 500mg) l CEJ (Cetrizine Hydrochloride EYE REFRESHER (Sodium Carboxymethylcellulose 0.5%) dants) l GLOWRICH-AZ (Carbonyl iron, Folic Acid,, Vitamins & 10mg) l CETOM-L (Levocetrizine Dihydrochloride 5mg) l Mob:- 09810060234, 09911193164. Zinc.) l HICLOX-LB (Amoxycillin 250 mg.+ cloxacillin 250 mg, CETOM-PLUS DT (KID) (Levocetrizine 2.5mg, Montelukast 4mg) +Lactic Acid Bacillus 60 millionspores ) l LYCOSHINE (Lycopene CETOM-PLUS (Levocetrizine 5mg, Montelukast 10mg) l 5000 mcg + Vit.A 2500 I.U + Vit E 20mg + Vit.C 50 mg + Zinc l QUEST PHARMACEUTICALS CIPROM-500 (Ciprofloxacin 500mg (White Tablet)) CROMOL 27.45 mg + Selenium 70 mcg.) l OCINIL-20 (Omeprazole 20 DT-650 (Paracetamol 650mg DT)DIC-SP (Diclofenac 50mg, Para TABLETS:- ARNOLD- DT (Nimesulide 100 mg.Disp.Tablets) l ARNOLD-P (Nimesulide 100 mg + Paracetamol 500 mg) l CAL- mg.) l OCINIL-D (Omeprazole 20 mg + Domperidone10 mg) l 325mg, Serratiopeptidase 10mg) l DICLOM-PLUS (Diclo Sodium l ITRAQUEST-200 (Itraconazole 200mg) l QUBACT-SB (Pre & 50mg+Paracetamol 325mg) DICLOM-PLUS (Diclo Potassium CAD-500 (Calcium Carbonate1250 mg +Vitamin D3 250 I.U.) CHECKSPAS (Clidinium Bromide 2.5 mg + Chlordiazepoxide 5 Probiotic with L-Glutamine) l QUPRAZ-DSR (Pantoprazole 40 50mg+Para. 325mg (BROWN PVC) l DICLOM-SP (Diclo l mg + Domperidone 30 mg S.R) l QUPRAZ -LSR (Pantoprazole Potassium 50mg + Serratiopeptidase 10mg) DICLOM-ZOX mg + Dicyclomine10 mg) CAMFLEX-P (Lornoxicam 8 mg + Paracetamol 325 mg) l CAMFLEX-P (Lornoxicam 8 mg + 40 mg + Levosulpiride 75 mg S.R) l QUPRAZ -LSR (Diclo. Pota. 50mg + Para 325mg + Chlorzoxazone 250mg) l Paracetamol 325 mg) l CORTIPRIV-6 (Deflazacort 6 mg) l (Pantoprazole 40 mg + Levosulpiride 75 mg S.R) EGOUT-90 (Etoricoxib 90mg) l EGOUT-120 (Etoricoxib 120mg) l CEEZ-GM (Diacerin 50 mg + Glucosamine 750 mg + Methyl Mob:- 09888525668, 099814645668. jkeHkjksls py jgk thouT;ksr vLirky ykap gqvk igyk oSDlhus'ku fDyfud] ?kj&?kj tkdj uotkrksa dks yxk,xk Vhds iatkc%& izsl lfpo iatkc dsfeLV ,lksfl,'ku ifV;kyk Jh galjkt esgrk eks- 9814132529 ds }kjk DokyhiQkbZ MkWDVj ;g ns'k es igyh ckj gqvk gS fd vc uotkrksa dks Vhds yxokus ds fy, vkidks vLirky ugh tkuk iM+sxk- ds cxSj gh py jgk gS thouT;ksr eYVhLis'kfyVh vLirky- MªkbZoj vkSj lgk;d ds }kjk gha ejhtks dk mipkj gks vc Vhds yxkus ds fy, ,slk fDyfud rS;kj fd;k gS tks ?kj] Ldwy] dkWyst vkSj nÝrjksa esa tkdj uotkrksa jgk gSa- vLirky esa ejhtksa dk bykt gsYij ds Hkjksls gh py jgk gS- vLirky esa tc LokLF; foHkkx us Nkik ekjk f'k'kqvksa dk Vhdkdj.k djsxk- oSDlhus'ku vkWu OghYl uke ds bl izkstsDV dh 'kq:vkr iq.ks ls gks jgh gS- rc 13 ejht HkrhZ Fks ftuesa ls 5 ejhtksa ds vkWijs'ku Hkh gq,- LokLF; foHkkx us lgk;d flfoy ltZu MkW- jes'k dSls igqapsxk fDyfud ?kj rd& oSDlhus'ku vkWu OghYl njvly ,d okgu esa rS;kj fDyfud gS ftlesa dqekj dh vxqokbZ esa ;gka Nkisekjh dj dbZ [kkfe;ka mtkxj dha- vxj vLirky esa ,slk gh pyrk jgk gS rks ejhtksa cPpksa dks yxus okys Vhds ekStwn gksaxs- bu pyrs&fiQjrs fDyfud dks lcls igys bu bykdksa es Hkstk tk,xk dh tku Hkh tku ldrh gSa- gkaykfd flfoy ltZu MkW- izHknhi dkSj dks fyf[kr f'kdk;r feyh Fkh fd thouT;ksr tgka ij Vhdkdj.k dh nj de gS vkSj nwj ds bykdkssa esa ekStwnk Ldwyksa vkSj dkWystksa esa Hkh bl fDyfud vLirky esa Hkkjh dfe;ka py jgh gSa- LokLF; foHkkx tc Vhe vLirky igqaph rc vLirky esa u rks MkWDVj Fkk vkSj dks cM+s vklkuh ls igqapk;k tk ldsxk- efgykvksa ds vkWfiQl esa Hkh bl fDyfud dks igqapkdj Vhdk fn;k u gh iQkekZflLV- yscksjsVªh [kqyh Fkh] ysfdu mlesa dksbZ ySc VsfDuf'k;u ugha Fkk- vLirky ds eSMhdy LVksj esa nok tk ldrk gS- bl u, pyrs&fiQjrs fDyfud dh 'kq:vkr iq.ks ls dh tk jgh gS- vkbZ vkbZ Vh gSnjkckn forj.k djus ds fy, iQkekZflLV Hkh ugha Fkk- tc LokLF; foHkkx us Nkik ekjk rc ogka gjiky flag uked O;fDr LFkkuh; uxj fuxe ds lkFk feydj u;k oSDlhus'ku fDyfud pyk,xh- ,d ckj bldk liQy ijh{k.k gks igqapk mlus [kqn dks vLirky dk ekfyd crk;k- Vhe us mlls MkWDVj u gksus dh iwNk rks mlus dgk gS MkWDVj 'kke tkus ds ckn bls iwjs ns'k esa ykxw djus dh ;kstuk gS- Vhdkdj.k dk ;g rjhdk vPNk lkfcr gksxk& ,d dks vkrs gSa- Vhe us MkWDVj dk fjdkWMZ fn[kkus dks dgk] ij gjiky flag fjdkWMZ ugha fn[kk ik,a- lgk;d flfoy ltZu tkudkj ds vuqlkj ;g fDyfud Vhdkdj.k tkx:drk dk dke Hkh dj ldrk gS- ftu bykdks ls LokLF; us MkW- jes'k dks dM+h iQVdkj yxkrs gq, psrkouh nh- fd Hkfo"; esa ;s lc nksckjk uk nksjk;k uk tk,a- dsanz nwj gSa ogka ij igaqpk ikuk bl fDyfud dks lEHko gS- blls yksxksa dks dkiQh jkgr nh tk ldrh gSa- Piramal Group Partners With IIFL Wealth on an AIF to Provide Last-Mile Funding for Select Real Estate Projects Mumbai:- Piramal Group Ph.:- 022-38023000 and IIFL Wealth Management Limited (NSE: IIFLWAM) have announced a co-investment on an Alternative Investment Fund (AIF) platform to fund select advance stage / last-mile real estate projects across Tier 1 cities in India. This AIF with a target size of INR 2,000 crores, will be used to provide capital to Tier 1 developers in key markets. The market today presents many opportuni- ties for last-mile finance across projects that require a minimum amount of gap funding for completion. Piramal Group has a long-standing track record of both primary development and wholesale funding in real estate. It also has a fiduci- ary fund manage- ment business across multiple funds and man- dates across structured, pre- ferred and pure equity. IIFL Wealth is one of the lead- ing wealth man- agers in the coun- try today, with aggregate assets of around INR 1,70,000 crores under manage- ment, advice and distribution. Headquartered in Mumbai, IIFL Wealth Management has more than 950 employees and presence in 6 major global financial hubs and 23 loca- tions in India. Khushru Jijina, Managing Director, Piramal Capital & Housing Finance Ltd said, “The creation of this AIF is in line with Piramal Group’s strategy to build newer platforms for co-lending with liked-minded reput- ed institutions. We will initially seed the fund with existing loans from Piramal Group’s portfolio, while continu- ing to explore quality deals from the market in future.” With this, Piramal will also be facilitating external capital (on a fund or co-investment basis) alongside its lending business. This will enable Piramal Group to continue to further grow the lending business through a new co-investment / co-origination model. nok O;kikfj;ksa us trk;h gennhZ xksj[kiqj%& ,d ifjokj vkfFkZd raxh ls tw> jgk gSa- cchrk vius ifr larks"k JhokLro dk bykt djkus esa vkfFkZd :i ls iwjh rjg VwV pqdha gSa- cchrk us bykt ds fy, viuh iwjh laifRr o tsoj vkfn cspdj yxHkx 72 yk[k :i;s [kpZ dj fn;s- vc vkxs muds ikl bykt ds fy, #i;s ugha gSa- bl le; oks vkfFkZd raxh ls tw> jgh gSa- tSls gh nok O;kikfj;ksa dks bldh tkudkjh feyh mUgksus enn djus ds fy, gkFk Ck<+k;k 40 gtkj #i;s dh nok,a] lftZdy o vU; t:jh lkeku iznku fd;k vkSj vkxs Hkh djus dk vk'oklu fn;k- nok foØsrk ds vè;{k o egkea=kh vkyksd ¶tks O;fDr uezrk ds vk/kj ij pkSjfl;k ds usr`Ro esa nok O;kikfj;ksa dk ,d izfrfuf/ eaMy cchrk JhokLro ds ?kj igaqpk- mUgksus vke yksxks ls Hkh vihy dh bl rjg ds ifjokj dh enn djuk ,d balkfu;r gSa- bl volj ij la;kstd larks"k JhokLro] la;qDr ea=kh fnyhi dqekj xqIrk] ihvkjvks v'kksd xqIrk vkfn mifLFkr lcls rkyesy cuk, j[k ldrk gS] Fks- nok O;kikfj;ksa us bldh enn djrs gq, dgk gS fd ge vkxs Hkh enn djrs jgsaxs- og egku gS¸ www.medicaldarpan.com Product List Farma Hub Domeperidone 30mg) l Farclox (Ampicillin 250mg + Dicloxacillin 250 mg) l Farnac Rz (Aceclofenac 200mg + Rabeprazole 20 mg) l Lycofar (Lycopene 10% 5000mcg + Beta Carotene Tablets:- Akon-Xt (Ferrous Ascorbate Eq. to Lron 100mg + Folic Acid 1.5mg) l Amress-Al (7.5% dispersion) 20mg + Mecobalamin 250mcg + Vitamin B6 3mg + Folic Acid 1.5mg + Chromium (Amlodipine 5 gm + Atenolol 50 mg) l Anlin-400 (Theophyllin Prolonged Rekease Ip 400 mg) l Picolinate 75mcg + Green Tea Extract 50% 200mg + Sodium Selenite100mcg + Zinc Sulphate Azixime (Azithromycin 250 mg + Cefixime 200 mg) l Azixime LB (Azithromycin 250 mg + Cefixime Monohydrate 27.453mg) l (Mecozone-Pg (Mecobalamine 750mg + Pregabalin 75 mg) l Moxyzan 200 mg + Lactic Acid 60 Million Spores) l Azixime Plus (Azithromycin 500 mg + Cefixime 200 mg) 250 (Amoxycillin 250 mg) l Moxyzan 500 (Amoxycillin 500 mg) l Necessity (Methylcobalamin l Candifine Tf (Ltraconzole 100 mg + Terbinafine 250 mg) l Cefafar 250 Cefuroxime Axetil 250mg) 1000mcg + Benfotiamine 100mg + Pyridoxine Hcl 1.5mg + Alpha Lipoic Acid 0.75mg) l Panfar Dsr l Cefafar 500 Cefuroxime Axetil 500mg) l Cefafar Cv 250 (Cefuroxime Axctil 250mg + Potassium (Pantoprazole Sodium 40mg + Domeperidone 30mg) l Panfar-L (Pantoprazole 40 mg + Clavulanic 125mg) l Cefafar Cv 500 (Cefuroxime Axetil 500mg + Potassium Clavulanic 125mg) l Levosulpiride 75 mg) l Platimmune (Carica Papaya Extract 200 mg Cefizan Plus (Cefixime 200mg + ofloxacin 200mg) l Cefizna S + Tinospora Extract 150 mg + Goat Milk Powder 100 mg + Vitmin E (Cefixime 200 mg + Sulbactam 150 mg) l Cefiway 200 Bb (Cefixime 200 mg + Lactic Acid 60 Million Spoers) Cefiway Plus 40 mg + Wheatgrass Extract 50 mg + Kiwi Extract 50 mg + Pomegranates 50 mg) l Rabyfar-DSR (Rabeprazole Sodium 20mg (Cefixime 200mg + Ofloxacin 200mg + Lactic Acid Bacillus) l + Domepridone 30mg) l Rabyfar IT (Rabeprazole Sodium 20mg + Cefiway Oz (Cefixime 200mg + Omidazole 500mg) l Chestwin Itopride 30mg) l Rabyfar L (Rabeprazole 20 mg + Levosulpride 75 (Paracetamol 325mg + Cetirizine 5 mg + Phenylephrine10mg) l mg) l Silyzan (Silymarin, L-Omithine, L-Aspartate, Folic Acid, Clonazan-Et (Clonazepam 0.5mg + Escitalopram Oxalate 10mg) l Nicotinamide, Calcium D-Pantothenate, Thiamine Mononitrate, Defahub 6 (Deflazacort 6mg) l Doxyfine (Doxylamine Succinate Riboflavin & Pyridoxine Hydrochloride) l Zynagut (Prebiotic & 10mg + Pyridoxine Hydrochloride 10 mg) l Drotyfar-M (Drotaverone Probiotic Cap) l Zactovit Liquid:- Akon Xt (Ferrous Ascorbate Hcl 80mg + Mefanamic Acid 250mg) l Etohub 0.5 (Etizolam 0.5 220.5 mg + Elemental Iron 30 mg + Folic Acid 550 mcg) l Akon Xt mg) l Etohub 0.25 (Etizolam 0.25 mg) l Ex-Cv 375 (Amoxycillin (Ferrous Ascorbate 220.5 mg + Elemental Iron 30 mg + Folic Acid Trihydrate 250mg + Clavulanic Acid 125mg) l Ex-Cv 625 550 mcg) l Apyfar (Cyproheptadine Hcl Ip 2mg + Tricholine Citrate (Amoxycillin Trihydrate 500mg + Clavulanic Acid 125mg) l Ex-Cv 275mg) l Chestwin (Paracetamol 125 + Cetirizine 2 mg + 625 Lb (Amoxycillin Trihydrate 500mg + Clavulanic Acid Bacillus) l Farchav-375 (Amoxycillin Trihydrate 250mg + Clavulanic Acid Pheylephrine 5 mg) l Covent-LC (Codeine Phosphate 10mg + Triprolidine Hydrochloride 1.25mg) l Covent-LC (Codeine 125mg) l Farchav-625 (Amoxycillin Trihydrate 500mg + Clavulanic Phosphats 10mg + Chloropheniramine 4mg) l Coviplex (Lycopene Acid 125mg) l Farclav-Kid (Amoxycillin Trihydrate 200mg + 6% 2000 mcg + Niacinamide 25 mg + Pyridoxine Hydrochloride 1.5 Clavulanic Acid 28.5mg) l Farcof Cold (Paracetamol 325 mg + Guaiphenesin 100 mg + Ambroxol mg + Cyanocobalamin 1 mcg + Sodium Selenate 10 mcg + Zine Gluconate 3 mg + Potassium 30mg + Phenylephrine 10 mg + Cpm 10 mg) l Farcort 4 (Methyleprednisolone 4 mg) l Farcort 8 Lodine 100 mcg + Manganese Sulphate 2 mg + Copper Sulphate 500 mcg Flavour Base Syp.) l (Methyleprednisolone 8 mg) l Farcort 16 (Methyleprednisolone 16 mg) l Farcoxia (Etoricoxib 90 Defahub (Deflazacort Oral Suspension 6mg) l Farcof-AB (Ambroxol 15mg + Terbutaline Sulphate mg) l Farnac-forte (Trypsin 48mg + Bromelain 90mg + Rutoside 100mg + Diclofenac Potassiun 1.5mg + Menthol 1mg) l Farcof-CD (Codeine Phosphate 10mg + Chloropheniramine 4mg) l 50mg l Farna-p Aceclofenac 100mg + Paracetamol 325mg) l Farnac-p (Alu-Alu) (Aceclofenac Farcof-D (Chlorpheniramine Maleate 2 mg + Dextromethorphan 100mg + Paracetamol 325mg) l Farnac-Mr (Aceclofenac Hydro Bromide 10mg + Phenylephrine Hydrochloride 5mg (With 100mg + Paracetamol 325mg + Chlorzoxazone 250mg) l Farnac-sp (Aceclofenac 100mg + Paracetamol 325mg + Carton) l Farcof- LS (Levosalbutamol Hydrochloride 1 mg + Ambroxol Hydrochloride 30 mg + Guaiphenesin 50 mg) l Serratiopeptidase 15mg) l Faranc-th4 (Aceclofenac 100mg + Farcof- P (Paracetamol 125mg + Chloropheniramine Maleate Paracetamol 325 mg + Thiocolchicoside 4mg) l Farpod-O 1mg + Dextromethorphan Hydrobromide 5mg) l Farcof-Sf (Cefpodoxime Proxetil 200mg + Ofloxacin 200 mg) l Farpod (Chlorpheniramine Maleate 2 mg + Dextromethorphan 100 (Cefpodoxime Proxetil 100mg) l Farpod 200 (Cefpodoxime Hydrobromide 10mg + Phenylephrine Hydrochioride 5mg (With Proxetil 200mg) l Farpod CV (Cefpodoxime Proxetil 200 mg + Carton) (Sugar Free) l Farlax (Lactulose 10gm) l Farnac-P Pot. Clavulanate 125mg) l Farzyme Pancreatin 170 mg + (Aceclofenac 50mg + Paracetamol 125mg (With Carton) l Activates Dimethicone 80 mg) l Febufar 40 (Febuxostate 40 Farzyme (Fungal Diastase 50 mg + Pepsin 10 mg) l Farflux-O mg) l Fixim 100 Dt (Cefixime Trihydrate 100mg) l Fixim 200 Dt (Sucralfate 1 mg + Oxetacaine 20 mg) l Joycin OZ (Cefixime Trihydrate 200mg) l Fixim 400 (Cefixime Trihydrate (Levofloxacin 125 mg + Ornidazole 125 mg) l Kalen (Calcium 400mg) l Fixim-Lb 50 Dt (Cefixime With Lactic Bacillus 50mg) Carbonate With Vitamin D3 Suspension) l Lycofar (Lycopene l Fixim Plus (Cefixime Trihydrate 200mg + Ofloxacin 200mg) l 6% Minerals With Antioxidant Syp) l Necessity (L-Lysine Fungifar 250 (Terbinafine 250 mg) l Fungifar 500 (Terbinafine Hydrochloride 10.0mg + Lycopene 6% Omcg + Vitamin A 1250. 500 mg) l Glyzan M1 (Glimepride 1 mg + Metformin Oip + Cholecalceferol 100.Oip + V Vitamin E S Oip (As D-L Alpha Hydrochloride 500 mg) l Glyzan M2 (Glimepride 2 mg + Tocopheryl Acetate) + Cyanocobalamin 0.5mcg + Sodium Metformin Hydrochloride 500mg) l Glyzan Mv1 (Voglibose 0.1mg + Glimepride 2.0mg + Metformin Hydrochloride 500mg) Selenate Eq. To Selenium 17.5mcg + Vitamin C 25.Omcg + Thiamine Hydrocloride 1.0 mg + Riboflavin Sodium Phosphate l Glyzan Mv2 (Voglibose 0.2 mg + Glimepride 2.0 mg + 1.5mg + Pyridoxime Hydrochloride 0.75mg + Copper Sulphate Metformin Hydrochloride 500 mg) l Ishufee (Flupentixol 0.5 mg 100.Omcg + Potassium Iodide 50.Omcg + Zinc Sulphate Eq. To + Melitracen 10 mg) l Joycin-500 (Levofloxacin 500mg) l Elemental Zinc 1.5mg In A Flavoured Syrupy Base) l Parahub Joycin Oz (Levofloxacin 250mg + Ornidazole 500 mg) l Kalen Ds (Paracetamol 250mg) l Parahub MF (Mefenamic Acid 50mg (Calcium Citrate 100mg + Calcitrol 0.25mg) l Kalen K2 + (Vitamin K27 45mcg + Calcium Citrate 1000mg + L-Methylfolate + Paracetamol 125mg) l Pulmozan (Acebrophylline 50mg + Guaiphenesin 50mg + Terbutaline Sulphate 1.25mg) l Raceone 1mg + Cissus Quadrangularis 500 mg + Vitamin D3 1000 Ui) l (Raceadotril Ip 10 mg. Suspension) l Silyzan Syp (Silymarin Le-Jig (Levocetrizine 5 mg) l Linifine (Linezolid 600 mg) l With B-Complex Susp.) l Utility (Uterine Tonic) l Vanbion-L Lumefar (Artemether 80mg + lumefantrine) l Metfar-500 (Thiamine Hydrochloride 2mg + Riboflavine Sodium Phospate (Metformin 500 mg) l Moxyzan 250 DT (Amoxycillin Dispersible 2.5 mg + Pyridoxine Hydrochloride 0.75 mg + Niacinamide 15 mg Tablets 250 mg) l Necfine-p (Diclofenac Sodium 50 mg + + D-Panthenol 3 mg + Cynocobalamin 1 mcg + L-Lysine 375 mg) Serratiopeptidase 10mg + Paracetamol 325mg) l Nipafar l Veebaz 200 (Azithromycin Dihydrate 200mg) l Ventmino LS (Nimesulide 100mg + Paracetamol 325mg) l Ketofar Junior (Levosalbutamol Hydrochloride 1 mg + Ambroxol (Ketoconazole 200 mg) l Panfar 40 (Pantoprazole 40 mg) l Hydrochloride 30 mg + Guaiphenesin 50 mg) Liquid:- Windfar Panfar D (Pantoprazole 40 mg + Demeperidone 10 mg) l L (Montelukast Sodium 4 mg + Levocetirizine Dihychloride 2.5 Parahub 650 (Paracetamol 650 mg) l Parahub D (Paracetamol mg) l Wisoflox (Ofloxacin 50mg/5ml) l Wisoflox-OZ 325 mg + Demoperidone 10 mg) l Rabyfar 20 (Rabeprazole 20 (Ofloxacin 50mg + Ornidazole 125mg) l Zanfast Magaldrate mg) l Tamsufar-D (Tamsulosin 0.5 mg + Dustasteride 0.4 mg) 480 mg + Simethicone 20 mg + Domperidone 10 mg) l Zanfast l Tanmink 20 (Telmisarten 20 mg) l Tanmink 40 (Telmisartan (Magaldrate 480 mg + Simethicone 20 mg + Domperidone 10 40 mg) l Tanmink 40 H (Telmisartan 40 mg + mg) l Zanfast OX Oxetacaine 10 mg + Aluminium Hydroxide Hydrochlorothiazide 12.5 mg) l Texazan- MF (Tranexamic 291 mg + Magnesium 98 mg) l Zanliv (Strong Liver Tonic) Dry Acid 500 mg + Mefenamic Acid 250 mg) l Tenzan Syrup:- Farpod (Cefpodoxime Proxetil 50mg / 5ml) l Farpad (Trifluoperazine HCL 1 mg + Chloradiazepoxide 10 mg) l 100 (Cefpodoxime Proxetil 100mg) l Farpod Cv (Cefpodoxime Tenifar-20 (Teneligliptin Hydrobromide hydrate 20 mg) l Tenifar-M (Teneligliptin Hydrobromide hydrate 20 mg + Proxetil I.P 50 mg + Potassium Clavulanate Diluted 31.25 mg) l Farclav (Amoxycillin 200mg + Clavulanic Acid 28.5mg) l Metformin 500mg) l Udifine 150(Ursodeoxycholic Acid 150mg) Farclav DS (Amoxycillin 400mg + Clavulanic Acid 57mg) l l Udifine 300 (Ursodeoxycholic Acid 150mg) l Udifine 300 Fixim (Cefixime Trihydrate 50mg / 5ml) l Zynagut (Prebiotic & (Ursodeoxycholic Acid 300mg) l Udifine SL (Ursodeoxycholic Probiotic Granules For Oral Suspension) l Linifine (Linezolid Acid 300mg + Silymarin 140 mg) l Vertizan 8/16 (Betahistine Dry Syp) Drops:- Akon (Iron Choline Citrate 50 mg + Lysine Hydrochloride Tablets IP 8 mg /16mg) l Veebaz 250 Hydrochloride 50 mg + Vitamin B12 2mcg + Folic Acid 100 mcg + Niacinamide 5 mg + Copper (Azithromycin Dinhydrate 250mg) l Veebaz 500 (Azithromycin Dihydrate 500mg) l Veebaz 500 Lb Sulphate 10 mcg + Zinc Sulphate Monohydrate 1 mg) l Colizan (Simethicone 40mg + Dill Oil (Azithromycin Dihydrate 500mg + Lactic Acid Bacillus) l Vomifine (Ondansetron 4 mg) l Windfar- 0.005ml + Fennel Oil 0.0007mg) l Farcof Cold (Paracetamol 125mg + Phenylepherine Hcl 5mg + Fx (Montelukast Sodium 10mg + Fexofenadin Hydrochloride IP120mg) l Windfar-L (Levocetrizine Chlorpheniramine Maleate 2mg) l Farpod PD (Cefpodoxime Proxetil) l Farzyme (fungal Diastase HCL 5mg + Montelukast Sodium 10 mg) l Wisoflox 200 (Ofloxacin 200mg) l Wisoflox-oz (1.800) 20mg + Caraway Oil 400 mcg + Cinnamon Oil 200 mg + Caradamon Oil 400 mcg + (Ofloxacin 200mg + Ornidazole 500mg) l Xcitement (Jar) Sildenafil Citrate 100 mg) l Xcitement Simethicone 40 mg + Petsin 10 mg) l Sai- Dom (Domperidon Suspension) l Vomifine (Strip) Sildenafil Citrate 100 mg) l Zanofiram (Disulfiram tablets IP) l Zan-M-Spas (Mefenamic Acid (Ondansetron 2 mg) l 250 mg + Dicyclomine Hydrochloride 10 mg) l Zincofar (Vitamins + Minerals + Natural Extract + Zincofar (Multiviamin Nutritional food Suppliments) Capsules:- Candifine (Itraconazole 100 mg) l Candifine-200 AUTHORIZED Drops) Mob:- (Itraconazole 200 mg) l Cindaplay-300 (Clindamycin 300 mg) l Dirham (Omeprazole 20mg) l 08171011413, DISTRIBUTORS Dirham-D (Omeprazole 20mg + Domeperidone 10mg) l Esofar-Dsr (Esomeprazole 40mg + 09837187230. OF ADR Book
Skin Care Tips For a Healthy And Glowing Skin In 30s Location Shop Name Contact No. 30s is the best time of your life. You have a stable career. Most probably stable-ish relationships, you have figured out Agra Satish Book Enterprises 9997877123 almost everything in your life by the time you are 30 except for one thing, a great skin. Yes, a great skin is a tough nut Allahabad Friends Book Depot 9451743891 to crack. If you are thirty, here are some skin care tips that might help you to get a beautiful skin. Take a look! l A healthy Amritsar Rajat Book corner 9417381838 lifestyle:- This one is the trickiest yet the most important thing. However, it is quite a simple phenomenon. If you are Amritsar Sunder Book Depot 9814074241 not healthy, you won’t shine. The glow, the beautiful skin that you long, the blemish free face, it all comes from within. Barnala Navchetan Book Shop 9779050692 If you are healthy, if you have a good working physical system, it will reflect as a natural glow. So, more or less, the Dhule Kushal Book shop 9423916592 beauty that people talk about is actually a healthy body. Give your body a good dose of natural antioxidants, Vitamins, Dimapur Modern Book Depot 9436006701 detoxifiers, and so on. Have a good night’s sleep, eat good, workout regularly. For the sake of a younger looking and Gwalior Unique Book Depot 9826257932 beautiful skin, maintain a healthy lifestyle, no matter how difficult it is. l Moisturise well:- Some of the early signs of age- Haldwani Pooram & Sons 9837092823 ing include crow feet, wrinkle, and fine lines and so on. When we age, our skin tends to dry out and lose the elasticity Jodhpur Book World 9829088088 with the lack of moisture. The mistake that we make as we age; we stop or hardly moisturise our skin, which ultimate- Kolkata Medicare Book House 9830518610 ly dries out our skin and causes the early signs of ageing such as wrinkles. Just moisturise your skin well, after show- Muzaffarnagar Royal Pustak Bhandar 9761313181 ers, every time you wash your face. Use moisturising creams and lotions or you can go for natural moisturisers such Nanded Debdhar Pustak Bhandar 9423615127 as honey and milk cream. l Stay hydrated:- Drink plenty of water to keep your naturally moisturised and hydrated. Nasik Rahul Book Center 0253-2599608 Deficiency of water can cause dry skin, drinking water daily can keep your skin moisturised along with hydrated; pre- Patna Current Book Services 9431077745 venting signs of ageing such as fine lines and wrinkles. l Protect your skin from dust and sun:- You may not know Raipur Srishti Medical Book House 9300855027 but the harmful UV rays are cause of 80 percent of skin ageing. Exposure to sunlight causes pigmentation, one of the Reewa Palak Medical Book 9893793577 early signs of ageing. Researches show that the impact of UV rays on skin can increase with age. Use a good sun- Tinsukia Sharma Book Stall 9435036146 block cream to protect your skin. l Live a stress-free life:- No matter how preachy it may sound but staying happy is Vishakhapatnam Andhra Medical Book Centre 9985716032 the secret to stay beautiful and young. Stress and worry can cause you to age faster. Yes, whether you are a guy or a For ADR Booking Poonam Singhal, Mob.- 09219444474, girl, stress has similar effect on you. You tend to have wrinkles faster. Smiling and staying away from stress is the key. Abhay Singhal, Mob:- 09319980483. Product List BLUEWATER RESEARCH (GLIMEPRIDE 2MG,METFORMIN 500MG (SR), PIOGLITAZONE Monohydrate 500 mg, l DYNACLIN Tab : Clindamycin HCL l l FLUTER-150 (FLUCONAZOLE 150MG) l BLUCAL-D3 (CALCI- 15MG) GLIMTER-PM2 (GLIMEPRIDE 2MG,METFORMIN 150/300mg, DOXYAID-LB Cap/Tab : Doxycycline Hyclate l l UM CARBONATE IP-1250MG,CALCIUM 500MG,VITAMIN D3 500MG (SR), PIOGLITAZONE 15MG) OLMIBLU-20 (OLME- 100mg and 5 Billion lactic acid bacillus spores, FUDICA Cream l l l 250 IU) l BLUCAL-CHEW (CALCIUM CITRATE MALATE SARTAN MEDOXIMIL 20MG) OLMIBLU-40 (OLMESARTAN : Fusidic acid 2%, NADIREST Gel : Nadifloxacin 1% , l 250MG,VITAMINE D3400IU,MAGNESIUM HYDROXIDE 50MG) MEDOXIMIL 40MG) OLMIBLU-20H (OLMESARTAN MEDOX- METATURNoint: Mupirocin2%, Antiallergic- E-BEST Tab : l l l BLUCAL-EASY (CALCIUM CITRATE MALATE 250MG,VITA- IMIL 20MG,HCTZ 12.5MG) OLMIBLU-40H (OLMESARTAN Mizolastine 10 mg, HYBEST-Tab : Hydroxyzine Hydrochloride l l l MINE D3400IU,MAGNESIUM HYDROXIDE 50MG) l BLUCAL- MEDOXIMIL 40MG,HCTZ 12.5MG) BLUPINE-5 (CILNIDIPINE 10/25mg , LORAID Tab : Loratadine 10 mg , LEVOCA l l l CC (CALCIUM CITRATE MALATE 250MG,CHOLECALCIFEROL 5MG) BLUPINE-10 (CILNIDIPINE 10MG) BLUFLOX-200 Tab/Syp : Levocetrizine Dihydrochloride2.5/5 mg, LEVOCA-M CONCENTRATE(POWDER FORM)EQ.TO CHOLECALCIFER- (OFLOXACIN 200MG) BLUFLOX-OZ (OFLOXACIN Tab : Levocetrizine Dihydrochloride 5mg &Montelukast Sodium l l l OL(VITAMIN D3)IP 100IU,FOLIC ACID IP 50MCG) l BLUCAL- 200MG,ORNIDAZOLE 500MG) AUTOFIXIM-200LB 10mg, POLBEST Tab : Dexchlorpheniramin Maleate SR 6mg, XT (CALCIUM CITRATE 1000MG, MAGNESIUM HYDROXIDE (CEFIXIME 200MG DT,LACTOBACILLUS 250MILLION FEX-UP Tab : Fexofenadine Hydrochloride 180 mg, l l l EQ. TO ELEM. MAGNESIUM 100MG,ZINC SULPHATE MONO SPORES) CEFFBLU-100 (CEFIXIME 100MG DT) CEFF- CALOMYNE Lotion : Calamine 8%, Glycerin 5%, Aloevera 10% l EQ. TO ELEM. ZINC 4MG, VITAMIN D3 200 I.U.) l BLUBEND- BLU-200LB (CEFIXIME 200MG DT,LACTOBACILLUS 250MIL- ,Liq. Paraffin10% & Zinc Oxide 3%, HYBEST ITCH LOTION: l l l PLUS (ALBENDAZOLE 400MG,IVERMECTIN 6MG) l LEVOT- LION SPORES) CEFF BLU-OF (CEFIXIME Pramoxine, Calamine & Aloe vera, Steroids - DYNACORT l ER (LEVOCETIRIZINE 5MG) l l LEVOTER-AM (LEVOCETI- 200MG,OFLOXACIN 200MG) CEFFBLU-CV (CEFIXIME 200 Tab : Deflazacort 6/12/30mg , SAFECORT Cream/Lotion l l RIZINE 5MG,AMBROXOL 60MG) l L-CID JUNIOR 15 (LENSO- MG,CLAVULANATE 125MG) CEFFBLU-AZ 250 (CEFIXIME :Mometasone Furoate 0.1%, ECZIVATE 30 Cream : Clobetasol l l PRAZOLE 15MG) l L-CID JUNIOR 30 (LENSOPRAZOLE 200 MG,AZITHROMYCIN 250MG) CEFFBLU-AZ (CEFIXIME Propionate 0.05%, HALOTURN Cream/lot. : Halobetasol l l 30MG) l LEVOTER-M KID (LEVOCETIRIZINE 2.5MG,MON- 200 MG,AZITHROMYCIN 500MG) CEFFBLU-OZ (CEFIXIME Propionate 0.05%, FLUTURN-H Cream : Fluocinolone l l TELUKAST 5MG (BILAYERED) l LEVOTER-M (LEVOCETI- 200MG,ORNIDAZOLE 500MG) CEFFBLU-LZ (CEFIXIME Acetonide 0.1%, NADIREST-M Cream : Nadifloxacin 1% l l RIZINE 5MG,MONTELUKAST 10MG (BILAYERED) l 200MG,LINEZOLID 600MG) FUROBLU-250 (CEFUROXIME &Mometasone Furoate 0.1% , DESOCARE Lotion : l l FEXOBLU-M (FEXOFANADINE 120MG,MONTELUKAST 10MG AXETIL 250MG) FUROBLU-500 (CEFUROXIME AXETIL MicronisedDesonide 0.05%, ECZIVATE-SLotion : Clobetasol l l l (BILAYERED) l LEVOTER-PLUS (LEVOCETIRIZINE 500MG) EZONID (LINEZOLID 600MG) FPM-200 (FAROPE- Propionate 0.05% & Salicylic Acid 3/6% , ECZIVATE-S6% l l 5MG,MONTELUKAST 10MG,ACEBROPHYLLINE 200MG(SR) l NAM SODIUM EXTENDED RELEASE 200MG) TEMIPRO-375 OINT: Clobetasole Propionate 0.05% & Salicylic acid 6%, l LEVOTER-FORTE (LEVOCETIRIZINE 5MG,MONTELUKAST (SULTAMICILLIN 375MG) BLUPOD-100DT (CEFPODOXIME ISORVATE-AL Gel : Clobetasol propionate 0.05% &Ammonium l l l 10MG,AMBROXOL 75MG) l CARDIVAX-10 (ATORVASTATIN 100MG) BLUPOD-200 DT (CEFPODOXIME 200MG) BLU- Lactate 12%, FUDICA-B Cream : Fusidic acid 2% & l 10MG) l CARDIVAX-20 (ATORVASTATIN 20MG) l CARDI- POD-OF (CEFPODOXIME 200MG,OFLOXACIN 200MG) Mometasone Furoate 0.1% , Antifungal - ITRASTAT Cap : l VAX-10CL (ATORVASTATIN 10MG,CLOPIDOGREL 75MG) l BLUPOD-AZ (CEFPODOXIME 200MG,AZITHROMYCIN Itraconazole 100/200mg, TERBAZ Tab : Terbinafine l CARDIVAX-20CL (ATORVASTATIN 20MG,CLOPIDOGREL 250MG) BLUPOD-CV (CEFPODOXIME 200 MG,CLAVU- Hydrochloride 250 mg, TERBAZ Cream/Dusting Powder : l l l 75MG) l CARDIVAX-10FT (ATORVASTATIN 10MG,FENOFI- LANATE125 MG) AZIBLOC-250 (AZITHROMYCIN 250MG) Terbinafine Hydrochloride 1%,K TZ Tab : Ketoconazole 200 l l BRATE 160MG) l CARDIVAX-10A (ATORVASTATIN AZIBLOC-500 (AZITHROMYCIN 500MG) CLARIBLU-250 mg, KTZCream/Dusting Powder : Ketoconozole 2%, KTZ
l l 10MG,ASPIRIN 75MG) l CARDIVAX-20A (ATORVASTATIN (CLARITHROMYCIN 250MG) CLARIBLU-500 (CLAR- Stay on lotion: Ketoconazole2% CANBEE Cream : l l 20MG,ASPIRIN 75MG) l AMITER-AT (AMLODIPINE ITHROMYCIN 500MG) LEVOZIP-500 (LEVOFLOXACIN Clotrimazole 1% , CANBEE-B Cream : Clotrimazole 1% l l 5MG,ATENOLOL 50MG) l BLUSARTAN-40 (TELMISARTAN 500MG) BLUCLAV-1GM (AMOXYCILINE 875MG,CLAVULAN- &Beclomethasone 0.025%, SERTAFIX Cream : Sertaconazole l l l HCL 40MG) l BLUSARTAN-40H (TELMISARTAN HCL IC ACID 125MG) BLUCLAV-625 (AMOXYCILINE Nitrate2%, K-WASH Shampoo : Ketoconazole 2%, K-WASH l l 40MG,HYDROCHLOROTHIAZIDE 12.5MG) l BLUSARTAN-AM 500MG,CLAVULANIC ACID 125MG) BLUCLAV-375 (AMOXY- PLUS Shampoo : Ketoconazole 2% & ZPTO 1%, FLUPACK l l (TELMISARTAN HCL 40MG,AMLODIPINE 5MG) l BLUSAR- CILINE 250MG,CLAVULANIC ACID 125MG) BLUMOL-650 Tab : Fluconazole 150 mg, LUNICOL Cream : Luliconazole l l l TAN-CT (TELMISARTAN 40MG, CHLORTHALIDONE 12.5MG) l (PARACETAMOL - 650DT) BLUMOL-1000SR (PARACETA- 1%, VORBERG Tab: Voriconazole200mg, AMLOTURN l l BLUSARTAN-AMH (TELMISARTAN 40MG,AMLODIPINE MOL 1000SR) PICTER-20 (PIROXICAM 20 DT) BLUMOL- Cream : Amorolfine HCL 0.025% , Immunosuppresants– l l 5MG,HCTZ 12.5MG) l BLUSARTAN-MT 50XL (TELMISARTAN SPAS (DICYCLOMINE HCL 20MG,PARACETAMOL 325MG) AZONYTab: Azathioprine 50mg, TACROGARD 0.1/0.03Oint : l 40MG,METOPROLOL 50MG (XL) l VASTABLU-10 (ROSUVAS- BLUMEF-SPAS (MEFENAMIC ACID 250MG,DICYCLOMINE Tacrolimus 0.1/0.03%, SORAPRINSoftgel Cap : Cyclosporine l l TATIN CALCIUM 10MG) l VASTABLU-20 (ROSUVASTATIN HCL10MG) BLUSPAS-MF (DROTAVERINE 80MG,MEFE- 100mg, NEOTURN 2.5/5/7.5 Tab : Methotrexate 2.5/5/7.5 mg, l CALCIUM 20MG) l VASTABLU-10F (ROSUVASTATIN CALCI- NAMIC ACID 250MG) BLUNIM-SP (NIMESULIDE Acne Care - ISOPEARL-M20Softgel Cap : Micronised l l UM 10MG,FENOFIBRATE 145MG) l VASTABLU-10A75 100MG,SERRATIOPEPTIDASE 10MG) BLUNIM-MD (NIME- Isotretinoin 20mg, ISOPEARL-10/20/30mgSoftgel Cap : l l (ROSUVASTATIN 10MG (AS POWDER FORM), ASPIRIN 75MG SULIDE 100MG (M.D ORANGE) BLUNIM-SPAS (NIME- Isotretinoin 10/20/30mg, DYNACLIN-N Gel : Clindamycin l l (AS ENTERIC COATED TABLET) (CAPSULES) l GLIMTER-MF SULIDE 100MG,DICYCLOMINE HCL10MG) BLUNIM-MR Phosphate 1% & Nicotinamide 4% , DYNACLIN Gel : l l 1 (GLIMEPRIDE 1MG,METFORMIN 500MG (SR) l GLIMTER- (NIMESULIDE 100MG,TIZANIDINE 2MG) BLUNIM-P (NIME- Clindamycin Phosphate 1%, O-GYL Gel : Ornidazole 10 mg, l l l MF 2 (GLIMEPRIDE 2MG,METFORMIN 500MG (SR) l SULIDE 100MG,PARACETAMOL 325MG) BLUFEN-P (ACE- ADAQUEENGel : Adapalene 0.01%, ADAQUEEN-C Gel : l l GLIMTER-MF1 FORTE (GLIMEPIRIDE 1MG,METFORMIN CLOFENAC 100MG,PARACETAMOL 325MG) BLUFEN-MR Adapalene 0.01% & Clindamycin Phosphate 1%, TRET-A 1000MG (SR) l GLIMTER-MF2 FORTE (GLIMEPIRIDE (ACECLOFENAC 100MG, PARACETAMOL 325MG,CHLORZOX- Cream : Tretinoin 0.025%,AZICA Gel : Azithromycin Dihydrate l l 2MG,METFORMIN 1000M (SR) l FORBLU-0.2 (VOGLIBOSE AZONE 250MG) BLUFEN-SP (ACECLOFENAC 2%, BENZITURN-AD Gel : Benzoyl peroxide 2.5% & l 0.2MG,METFORMIN 500MG) l FORBLU-0.3 (VOGLIBOSE 100MG,PARACETAMOL 325MG,SERRATIOPEPTIDASE 10MG) Adapalene 0.1%, Benziturn Gel : Benzoyl peroxide 2.5/5/10%, l l 0.3MG,METFORMIN 500MG) l GLIMTER-MV 2.2 BLUFEN-PLUS (ACECLOFENAC 100MG,THIOCOLCHICO- Hyperpigmenting -AZESPOT Cream : Azelaic acid 15 %, l (GLIMEPRIDE 2MG,METFORMIN 500MG (SR),VOGLIBOSE SIDE 4MG) BLUFEN-TH (ACECLOFENAC 100MG,PARAC- FACELITE Gel : Kojic Acid Dipalmitate2%, Arbutin 0.2MG) l GLIMTER-MV 2.3 (GLIMEPRIDE 2MG,METFORMIN ETAMOL 325MG,THIOCOLCHICOSIDE 4MG) 1.5%,Octinoxate 7.5%, Vitamin-E Acetate1%, Mulberry l 500MG (SR),VOGLIBOSE 0.3MG) l GLIMTER-MV 1.2 Mob:- 09317777888. Extract1% & Glycolic Acid 10%, M-LITE PLUS Cream : (GLIMEPRIDE 1MG,VOGLIBOSE 0.2MG,METFORMIN 500MG Hydroquinone 2%,& Tretinoin 0.025%, l M-LITE FORTE Cream (SR) l GLIMTER-MV 1.3 (GLIMEPRIDE 1MG,VOGLIBOSE E-Derma Pharma India Pvt. Ltd. : Hydroquinone 2%, Tretinoin 0.025%& Mometasone Furoate Antibiotics - AZICA Tab: Azithromycin Dihydrate 250/500mg, l l 0.3MG,METFORMIN 500MG (SR) l GLIMTER-PM1,7.5 0.1%, M-LITE GLOW Cream : Hydroquinone AUGFAST Tab: Amoxycillin Trihydrate 500mg& Potassium l (GLIMEPRIDE 1MG,METFORMIN 500MG (SR),PIOGLITAZONE 2%,Tretinoin0.025% &Fluocinolone Acitonide 0.01%, M- Clavulanate 125mg, l MINOPEARL Tab : Minocycline 7.5MG) l GLIMTER-PM2, 7.5 (GLIMEPRIDE 2MG,METFORMIN LITECream: Hydroquinone 2%, Hydrochloride 50/100mg, l CEFITURN Cap : Cephalexin 500MG (SR), PIOGLITAZONE 7.5MG) l GLIMTER-PM1 Mob:- 09034435000 09034635000. www.medicaldarpan.com FORTH COMING EVENTS January 4-6, 2020 India Med Expo 2020 Hyderabad, India. India Med Expo provide best oppor- 1LY, U.K. Tel.: +44 1332 226590, Email: enquiries@ prodentistry.co.uk ; Website: https:/ tunities to cover the enormous Indian healthcare market as well as considering the special poten- /www.professionaldentistry.co.uk/ events/uk-dental-congress tial of the big metropolitan areas with its growing demand and rising investments in the public and private healthcare sector. It will be held at Hitex ExhibitionCentre, Hyderabad, India. For details February 25-27, 2020 DUPHAT 2020 Dubai, UAE. DUPHAT opens great opportunity for contact: SD Medical Expositions, B-820, 8th floor, Noida One IT Park, B-Block, Sector-62, Noida- exhibitors to showcase advanced and latest products to different leading and pharmaceutical 201309, India. Tel.: +91-120-29-75517/2975518, M.:+91- 9311113921 and/or +91-8130998383, companies. It is a specialized E-mail: arun@ sdpromomedia.com ; Website: www.indiamedexpo.com zone created support the manu- facturing sector of the pharma January 9-12, 2020 Healthista Expo 2020 Casablanca, Morocco. The goal of Healthista Expo is industry from setup of plant to to bring manufacturers, medical equipment distributors and public & private decision makers rep- completion of theproduct. For resentinghealthcare professionals in Morocco together on the same professional platform, around details contact: INDEX® new medical technologies and the latest innovations. It will be held at The Office of Fairs and Conferences & Exhibitions Exhibitions (OFEC) of Casablanca, Morocco. For details contact: Eventista, 26, Rue Des Organisation Est., P.O.Box: Papillons, Oasis. Tel.: +212-660- 590012, E-mail: m.riad@ healthistaexpo.com ; 13636, Dubai, UAE. INDEX Website:www.healthistaexpo.com Holding Headquarters, Road # D- 62, Opposite Nad Al Hamar, January 12-15, 2020 Baghdad Turkish Health 2020 Baghdad, Iraq. Baghdad Turkish Health is Dubai, U.A.E. Tel: +971-4-520- medical, dental, pharmacy and health tourism sectoral Turkish export products fair. It will be held 8888, Email: info@ duphat.ae ; at Baghdad International Fair, Baghdad, Iraq. For details contact: Tüyap Fair Convention and Web.: www.duphat.ae Congress Center Cumhuriyet Mahallesi Eski Hadimköy Yolu Caddesi 9/1, 34500 Büyükçekmece, Istanbul, Turkey. Tel.: +90 (212) 867 1100, Fax: +90 (212) 8866698, Email:dilarademir- February 26-28, 2020 MEDICAL [email protected] http://baghdadhealthfair.com/ JAPAN 2020 OSAKA 6th Int’l Medical and Elderly Care Expo & January 23-26, 2020 MASICON Amravati 2020 Amravati, Maharashtra, India. The MASICON Conference Osaka, Japan. MED- Conference is themed as From Traditions to Trends and will provide the attendees with the oppor- ICAL JAPAN, consisting of 6 spe- tunity to gain insights relating to the basic principles of surgery up to the prevailing trends and the cialized shows: Medical Devices modern concepts in surgery. It will be held at Hotel Mehfil Inn, Amravati, India. For details contact: & Hospital Equipment Expo Corp Con Events, Plot No. 7, Opp Ramayana Cultural Hall , Above Take Away Hotel, Ulkanagari, OSAKA, Hospital BPO Services Aurangabad - 431005, India. Tel.: +91-942-2209890 and/ or +91-9130090435, E-mail: masi- Expo OSAKA, Medical IT Expo [email protected] ; Website: www.masicon2020.com OSAKA, Elderly care & Nursing Expo OSAKA, Community Care Expo OSAKA and Medical Device Development Expo OSAKA, is January 24-26, 2020 Autism Conference 2020 Muscat, Oman. The objective of the conference is Japan's leading trade show. It will be held at INTEX Osaka, Osaka, Japan. For details contact: to improve technical skills, boost international awareness and enhance collaborations and Reed Exhibitions Japan Ltd., 18F Shinjuku-Nomura Bldg., 1-26-2 Nishishinjuku, Shinj ku-Ku, exchange of ideas. Over the duration of the conference, the suggested themes will be tackled by Tokyo, 163-0570, Japan. Tel.:+81-3-3349-8586, Fax: +81-3- 3349-4922. Email: medical-japan@ the proposed international, regional and local experts. It will be held in Muscat, Oman. For details reedexpo.co.jp ; Website: http:// www.medical-jpn.jp/en-gb.html contact: K.I.T. Group Middle East FZ LLC, Association & Conference Management, P.O. Box 77893, Abu Dhabi, UAE. Tel.: +971-2-245-0057, Mob.: February 26-28, 2020 Future Materials 2020 Lisbon, +971-55- 295-0283, E-mail: [email protected] ; Portugal. Future Materials 2020 is comprised of various Website: www.kitgroup.org sessions designed to offer comprehensive symposiums that address current issue in the field of Materials January 27-30, 2020 Arab Health 2020 Dubai, UAE. Science and provides a fantastic opportunity to network Arab Health is the International Hospital, Medical with your peers from academia and industrialists which Equipment, and Services Exhibition & Conference. It is a includes professors, researchers, Materials Scientists, great opportunity where you can access all kinds of med- Materials Engineers, and Students. For details contact: ical products, innovations, and services under one roof. Yuktan Technologies Pvt Ltd, 1Raffles Place, #44-01A, It will held at Dubai World Trade Centre, Dubai, UAE. For One Raffles Place, Singapore-048616.Tel.: +65-9189- details contact : Informa PLC, 5 Howick Place, London, 1271. E-mail: [email protected] Website: SW1P 1WG, UK. Tel.: +44 (0) 20 7017 5000, Email: https://www. materialsconference.yuktan.com [email protected] ; Website: www.arab- healthonline.com Feb. 29 - 02 March, 2020 IWF 2020 Shanghai, China. IWF SHANGHAI Health, Wellness & Fitness Expo 2020 February 3-6, 2020 Medlab Middle East 2020 Dubai, is going to be held at Shanghai World Expo Exhibition UAE Medlab Middle East is a leading laboratory and and Convention Center, Shanghai, China. For details flagship exhibition and conference going to be held at contact: Shanghai Donnor Exhibition Service Co., Ltd., Dubai International Convention & Exhibition Centre, 16F, No. 441 North Henan Road, Jinyi Mansion, Dubai, UAE. For details contact: Informa Markets, 5 Shanghai, China. Tel. : +86-21-6610-2037, Fax: +86-21- Howick Place, London SW1P, 1WG, UK. Tel.: +971-4- 635-78500. E-mail: [email protected] ; Website: 4072488, E-mail: [email protected] www.ciwf.com.cn/en/ Website: www.medlabme.com March 1-3, 2020 CISILE 2020 Beijing, China. CISILE February 3-7, 2020 APMC Hyderabad 2020 Hyderabad, India. The APMC – an international 2020 is of foremost trade expo of Scientific Instrument & Laboratory Equipment in the world. The event is organized every four years under the auspices of CAPSM–Committee of Asia-Pacific upcoming is 18th edition of the China International Scientific Instrument & Laboratory Equipment Society for Microscopy (comprising of 17 countries). It will be held at Novotel Hyderabad Exhibition 2020 to be held in the national capital of the country at China National Convention Convention Centre, Hyderabad, India. For details contact: Blitz Events and Exhibition Pvt. Ltd., Center. For details contact: China Instrument Manufacturers Association/ Beijing Lamp Exhibition 156/A, MLA Colony, Banjara Hills, Road # 12, Hyderabad-500034, India. Tel.: +91-9848055227, Co., Ltd., Room 919 Quighe Quiangyou Building, Haidian District, Beijing,China.Tel. : 86-10- E-mail [email protected] ; Website: http:// www.apmc12.in 62919126, Fax: 86-10-62957691. Email:[email protected]; Website: http://en.cisile.com.cn February 7-8, 2020 Professional Dentistry London 2020 London, UK. Professional Dentistry London features a display of products such as laboratory equipment, dental design, complete March 4-6, 2020 Pharma Tech Expo 2020 Mumbai, India. The PharmaTech Expo an International design and print service, temporization and vitique for ceramic cementation and much more. With Exhibition on Pharma Machinery, Formulations, Nutraceutical, Lab, Analytical &Packaging its priority agenda, covering the latest knowledge updates and trends, this content-led education Equipment and will feature an exhibit of Pharma Machinery and Equipment, Pharma Formulation, programme is a key feature at Professional Dentistry. It will be held at Olympia London, London, API's Manufacturers, Ayurvedic & Nutraceutical Manufacturers, Cosmetic & Personal Care, UK. For details contact: Practice Enterprise Ltd., Macmillan Building, Parcel Terrace, Derby, DE1 Processing Plants & Machineries, etc. It will be held at Bombay Exhibition Centre (BEC), Mumbai, India. For details contact: Pharma Technology Index. Com Ltd., (A Division of KNS Group) 302, Shail’s Mall, Nr. Girish Cold Drinks, C.G. Road, Navarangpura, Ahmedabad- 380009, India. Tel.: +91-79-27540493, 40306340. E-mail: expo@ pharmatechnologyindex.com ; Web.: www.PharmaTechExpo.com/Mumbai
March 4-7, 2020 Hospital Infrastructure Show 2020 Kuwait. Hospital Infrastructure Show is an exhibition and conference and is one of the premier international healthcare events in the GCC. It will play host to the most important gathering of professionals and decision makers from around the GCC to meet, connect, exchange knowledge and conduct business. It will be held at Kuwait International Fairground, Kuwait City, Kuwait. For details contact: Atex International Exhibitions, 110, Clover Bay Tower, Marasi Drive, Business Bay, PO Box 413520, Dubai, UAE. Tel.: +971-4- 587-8627, M.: +971-52-417- 3686. E-mail: jerico.jan@ atexinternational.com ; Website: www.hospitalinfrastructureshow.com
March 5-7, 2020 Medical Fair India 2020 Mumbai, India. The Medical Fair India is the internation- al exhibition and conference for clinics, hospitals and health centers in India. It will be held at Bombay Exhibition Centre (BEC), Mumbai, India. For details contact: Messe Düsseldorf India Pvt. Ltd., 302-302A, 3rd Floor, Salcon Aurum Plot No. 4, Jasola District Centre, Near Apollo Hospital, Jasola, New Delhi- 110025, India. Tel.: +91- 11-4855 0061, Fax: +91-11-4855-0099. Email: med- icalliance@ messe-duesseldorf.com Website: www.medicalfairindia.com
March 6-7, 2020 Louisiana Orthopedic Association Meeting & Exhibition 2020 New Orleans, USA. Louisiana Orthopedic Association Meeting & Exhibition is an event that illustrates healthcare serv- ices, pharmaceuticals, medical products and services, orthopedics services, record management service, surgical products and much more. It will be held at Hilton New Orleans Riverside, New Orleans, USA. For details contact: Ruggles Service Corporation, 2209 Dickens Rd, Richmond, VA 23230, United States. Tel.: +804- 282-0062/ +225-933-5435. Email: [email protected] or [email protected] ; Website: https://www.louisianaortho.org/ exhibits/ iQkekZ IkQs;j dk liQy vk;kstu osnf'ko fctusl ehfM;k }kjk fnukad 6 ,oa 7 fnlEcj 2019 dks MsDdu dkWyst xzkmUM iq.ks esa ,d fo'kky iQkekZ iQs;j dk vk;kstu fd;k x;k- ftlesa iwjs Hkkjro"kZ ls yxHkx 45 iQkekZ dEifu;ksa us vius LVkWy ij vius mRiknksa dk izn'kZu fd;k- iQs;j esa iq.ks ds vykok eqEcbZ] uoh eqEcbZ] dksYgkiqj] vkSjaxkckn] 'kksykiqj] ukfld] tyxkao] ukxiqj] fnYyh] jktLFkku ,oa fons'kksa ls Hkh gtkjksa dh la[;k esa nok O;kikfj;ksa us fgLlk fy;k- izkIr tkudkjh ds vuqlkj esys esa vk;s nok O;olk;h vfr mRlkfgr fn[kk;h fn;s- lHkh nok O;olkf;;ksa us eSMhdy niZ.k ehfM;k gkÅl ds LVkWy ij Hkh viuh mifLFkfr ntZ djk;h tgk¡ ofj"B izfrfu/h vHk; fla?ky ,oa vfHk"ksd 'kekZ us mudk Lokxr fd;k- iQs;j dk mn~?kkVu MSCDA (egkjk"Vª LVsV dSfeLV ,UM MªfxLV ,lksfl;s'ku) ds lfpo% Jh vfuy ukoUnj eksñ 09730655555 us fd;k muds lkFk Jh cPpw HkkbZ vksloky vè;{k% osLV egkjk"Vª MSCDA vkSj tujy lsdsVªh Jh uUn fd'kksj lUnHkwj iq.ks dSfeLV ,lksfl;s'ku Hkh bl volj ij ekStwn jgs- fnukad 7 fnlEcj dks gfj;k.kk ds Mªx dUVªksyj Jh ujsUnz dqekj vkgqtk th us bl iQs;j dk mn~?kkVu fd;k vkSj iQs;j ds lekiu ij Jh fot; ikfVy LVsV izslhMsUV
egkjk"Vªk iQkekZ dkmfUly us iQs;j ds lHkh izfrHkkfx;ks dks vokMZ forfjr fd;s- Jh vfuy ukoUnj th us bl volj ij dgk dh ,sls esys vk;ksftr gksrs jgus pkfg;s] blesa ,d nwljs ls feyus ij vkil esa fo'okl iSnk gksrk gS vkSj O;kikj esa ikjnf'kZrk Hkh c<+ tkrh gS- ,sls gh ldkjkRed fopkj lHkh eq[; vfrfFk;ksa us bl volj ij fn;s- Jh vfuy ukoUnj th] Jh fot; ikfVy] Jh ujsUnz dqekj vkgqtk] Jh cPpq HkkbZ vksloky vkSj Jh uUn fd'kksj th ehfM;k gkÅl ds LVkWy ij Hkh igq¡ps- ;gk¡ Jh vfuy ukoUnj th us dgk dh eSMhdy niZ.k lekpkj i=k us ftl rjg iwjs Hkkjr o"kZ esa viuh esgur] yxu vkSj bZekunkjh ls tks igpku cuk;h gS oks okLro esa dkfcys rkjhiQ gS- ehfM;k gkÅl ds LVkWy ij eqEcbZ ls jk;xM izsflMsUV Jh gseUr yksudj] izsflMsUV Hkk;Unj Jh vjfoUn tSu] MksEchoyh(Bk.ks) ls nok O;kikjh Jh foosdkuUn Mkols] yksd'kkgh ehfM;k ls Jh uhys'kok.kh vkSj MksEchoyh ,lksfl;s'ku ls Jh jkts'k dksjis vkSj vU; lnL;x.k Hkh i/kjs- osnf'ko fctusl ehfM;k ds Mk;jsDVj Jh f'koe 'kekZ ,oa ch- ,l- HkUMkjh us lekiu ds volj ij tkudkjh nh fd iq.ks eas vkdj oks vkRefo'okl ls ycjst gSa] nok dEifu;ksa vkSj vkus okys nok O;kikfj;ksa dks ;gk¡ Hkjiwj ykHk feyk gS vkSj os Hkfo"; esa blh rjg ds ,sls iQs;j vk;ksftr djrs jgsaxs- f'koe 'kekZ ds vuqlkj vc os ekpZ 2020 esa t;iqj (jktLFkku) esa Hkh ,d fo'kky iQkekZ iQs;j dk vk;kstu djus tk jgs gS tgk¡ gtkjksa dh la[;k esa nok O;olkf;;h Hkkx ysaxs- & vHk; fla?ky] eksñ 09319982483- gkFkksa esa >u>ukgV gks ldrh gS ;s xaHkhj chekjh dEI;wVj ;k ySiVkWi ij yacs le; rd dke djus ls dbZ ckj gkFkksa esa >u>ukgV vkSj dykbZ dk nnZ tSlh leL;k;sa ns[kh tk jgh gSa- eSMhdy dh Hkk"kk esa bls dkiZy Vuy dgrs gSa- bl jksx ds y{k.kksa dks igpkuus ds ckn fcYdqy Hkh ykijokgh u cjrsa- vktdy ykssxksa esa gkFk o dykbZ dk nnZ ,d vke chekjh curk tk jgk gS- eSMhdy dh Hkk"kk esa bls dkiZy Vuy flaMªkse dgrs gSa- bls jksx esa tc vU; dksf'kdk;sa tSls fd fyxkesaV~l vkSj VsaMu lwt ;k iwQy tkrs gSa rks bldk izHkko eè; dksf'kdkvksa ij iM+rk gS- bl ncko ls gkFk ?kk;y ;k lqUUk eglwl djrk gS- dkiZy Vuy gfM~M;ksas vkSj dykbZ dh vU; dksf'kdkvksa }kjk cukbZ xbZ ,d ladjh uyh gksrh gS- ;g uyh gekjh eè; ukM+h dh lqj{kk djrh gS- eè; ukM+h gekjs v¡xwBs] eè; vkSj fjax vaxqfy;ksa ls tqM+h gksrh gS- lk/kj.kr;k dkiZy Vuy flaMªkse T;knk xaHkhj chekjh ugha gS- bykt ls ;g jksx nwj gks tkrk gS- ,d gh gkFk ls yxkrkj dke djus ls dkiZy Vuy flaMªkse dh ijs'kkuh gks ldrh gS- ;g lkekU;r;k mu yksxksa esa vf/drj ik;k tkrk gS ftuds is'ks esa dykbZ dks eksM+us ds lkFk fiafpax ;k xzhfiax djus dh t:jr gksrh gS- iq:"kksa dh rqyuk esa vkSjrksa dks bldk frxquk [krjk jgrk gS- vkSjrksa esa ;g lkekU;r;k ij xHkZkoLFkk ds nkSjku] esuksikst vkSj otu c<+us ds dkj.k Hkh gksrk gS- blesa os yksx Hkh 'kkfey gSa tks dEI;wVj ij dk;Z djrs gSa- blds vykok dkjisUVj] etnwj] laxhrdkj] eSdsfud] ckxokuh djus okys] lqbZ dk bLrseky djrs gq;s dbZ ?kaVksa rd dke djus] xksYiQ [ksyus vkSj uko pykus dk 'kkSd j[kus okys Hkh dkiZy Vuy flaMªkse dk f'kdkj gks ldrs gSa- ;g flaMªkse dqN chek- fj;ksa ls Hkh lEcfU/r gksrk gS tSls e/qesg] vkFkZjkbfVl ;k Fkk;jkWbM vkfn- ;g jkssx lcls igys baMsDl (rtZuh) ;k fefMy fiaQxj (eè;ek) dks izHkkfor djrk gS- ftlesa bu vaxq- fy;ksa esa tyu gksus yxrh gS- /hjs&/hjs ;g leL;k nnZ esa cny tkrh gS vkSj fiQj ;g nnZ vaxqfy;ksa ls dykbZ vkSj da/ksa rd igq¡p tkrk gS- fnu dh rqyuk esa jkr ds le; ;g leL;k T;knk ijs'kku djrh gS- dksbZ Hkh oLrq mBkrs le; vf/d ijs'kkuh gksuk- vaxwBs esa detksjh eglwl djuk- ;fn ;g jksx fdlh chekjh dh otg ls gS rks MkWDVj lcls igys ml leL;k dk bykt djrs gSa- fiQj og dykbZ dks vkjke nsus ds fy;s gkFkksa ds lgh ewoesaV dh lykg nsrs gSa- dykbZ esa fLIyaV cka/us dks Hkh dgk tk ldrk gS- dykbZ ij ciZQ j[kdj lsad dj ldrs gS- MkWDVj }kjk crkbZ xbZ LVªsfpax ,Dljlkbt ls Hkh ykHk gksrk gS- ,d gkFk ds ctk; nksuksa gkFkksa dks cjkcj dke esa ysa- T;knk nsj rd viuh dykbZ dks uhps >qdkdj u j[ksa- gkFkksa dks nckdj u lks;sa- gkFk dh ulksa ij ncko iM+us ls leL;k gks ldrh gS- gkFk] dykbZ vkSj vaxqfy;kasa dk O;k;ke djuk cgqr t:jh gksrk gS- fcuk O;k;ke ds vkidh dykbZ dBksj gks ldrh gS- le;≤ ij gkFkksa dh elkt Hkh t:j djsa- dqN ekeyksa esa bl chekjh dks iwjh rjg ls [kRe djus ds fy;s ltZjh dh t:jr gksrh gS- ltZjh ds dqN gÝrksa ;k eghuksa ckn okil dykbZ o gkFk dk lkekU; :i ls bLrseky dj ldrs gSa- bldh tk¡p izfØ;k esa lcls igys gkFk dks ,slh e'khu esa Mkyk tkrk gs ftlesa dqN nnZ ;k fctyh ds >Vds tSlh >u>ukgV eglwl gksrh gS- blds vykok ukM+h dh tk¡p ;k bysDVªksek;ksxzkiQh tk¡p djokbZ tkrh gS- ;g ns[kus ds fy;s fd vkids gkFkksa vkSj cktqvksa dh ukM+h o ekalisf'k;k fdlh izdkj ds dkiZy Vuy flaMªkse ds izHkkoksa dks fn[kk jgh gS ;k ugha- www.medicaldarpan.com
3 o"kZ rd ?kj cSBs ;g lekpkj i=k i<+us ds fy;s gekjs iatkc uS'kuy cSad ds [kkrk la[;k 1824002100120081] IFSC Code - PUNB0182400 tks fd eSMhdy niZ.k ds uke ls gS] esa :ú 250@& tek dj viuk iwjk irk gekjs iQksu uaú& 09410434811 ij SMS dj nsaA fy[kks eSMhdy 'kCn laxzg fy[k pqds cgqr J`axkj xhr Abdominocentesis mnj&xqgk esa fLFkr rjy dks ckgj fudkyus ds fy, mnj esa Nsn djuk] mnjNsnu- gSa fd, fuR; vfHklkj ehr Abdominocystic mnj rFkk fiÙkk'k; ls lacaf/r vc ns'k dky dh ckr fy[kks Abdominogenital mnj rFkk tuukaxksa laca/h dSlh gS Hkkjr ekr fy[kks Abdominohysterectomy isV esa phjk yxkdj xHkkZ'k; dks ckgj fudky nsuk e/qeklh fnu e/qe; jkrsa AbdominohysterotomyisV esa phjk yxkdj xHkkZ'k; esa phjk yxkuk Abdominopelvic mnj ,oa Jks.kh ls lacaf/r dha lnk izsejl dh ckrsa Abdominoperineal mnjewyk/kjh] mnj ,oa ewyk/kj laca/h fyD[kh ekSle dh vaxM+kbZ Abdominoplastic mnjla/ku laca/h vuqHko dh eknd iqjokbZ Abdominoplasty mnjla/ku ihys ljlksa ds iQwy fy[ks Abdominoscopy ,.MksLdksi uked ;a=k }kjk mnj&xqgk dk fujh{k.k djuk] mnj&tk¡p eu ds ekSle vuqdwy fy[ks Abdominoscrotal o`"k.kdks"k laca/h vc fy[kks ckr xn~nkjksa dh Abdominothoracic mnj ,oa o{k ls lacaf/r dqlhZ ds nkosnkjksa dh Abdominous cM+s isVokyk] rksanw nycnyq dk bfrgkl fy[kks Abdominovaginal mnj ,oa ;ksfu laca/h dqN vke fy[kks] dqN [kkl fy[kks Abdominovesical mnj ,oa ew=kk'k; laca/h Abducens 'kh"kZ vFkok djksfVraf=kdkvksa dk NBk tksM+k] viorZuh raf=kdk- fdl vksj gS Hkz"Vkpkj fy[kks Abducent vidf"kZ.kh] vilj.kd gks jgs fuR; O;fHkpkj fy[kks Abduct eè; js[kk ls nwj ys tkuk] vikorZu ;g tks dkyk /u [kkrs gSa Abducting vigj.k djuk] xSjdkuwuh :i ls ;k tcjnLrh mBkdj ys tkuk fj'or dk Hkksx yxkrs gSa Abduction gkFk&iSjksa dk 'kjhj dh eè; js[kk ls nwj ik'oZ esa tkuk ;k vaxqfy;ksa djrs ?kksVkyk fuR; u;k dk fdlh Hkqtk dh v{kh; (dsanzh;) js[kk ls nwj tkuk] vikorZu gS ftuesa ugha fcydqy g;k Abductor ,slh is'kh tks ladqfpr gksus ij 'kjhj ds fdlh vax dks 'kjhj dh eè; Vacancy for Marketing Managers fu’k,¡ jkst cnyrs gSa js[kk ;k dsanz ls nwj ys tkrh gS] viorZuh is'kh- We are Looking for marketing managers for franchise and third Abductor auris d.kZpkyd is'kh party for all over India on Lucrative terms. Blue Star Laboratories, dqlhZ ds fy, epyrs gSa dy dk¡xzsl ds lkFk [kM+s Abductor brevis pollicis vaxq"Bpkyd is'kh 206, Blue Star Plaza, Sarja Market, Opp. M2K, Sec.-7, Rohini, Abed 'kÕ;k ij] foLrj ij Delhi - 110085, Mob.: 09810165707 gS vkt lik ds lkFk tqM+s Abelmoschus mostachus yrkdLrwjh tks Fks clik ds gkFkh ij Aberrans Hkze.kdkjh] iFkHkz"V- dSfeLV ,.M MªfxLV iQsMjs'ku yVds gSa uy dh gRFkh ij Abenteric vk¡rksa ls ckgj fLFkr vax- vktex<+ ftys ds vè;{k o dsfeLV ,.M MªfxLV iQsMjs'ku] mRrj izns'k ds ukfer tks dey iQwy ds gkeh Fks Aberrant vlkekU;] foiFk] fo"ke- laxBu ea=kh lq/hj vxzoky }kjk lh-Mh-,iQ-;w-ih- ds ofj"B inkf/dkfj;ksa ds fo:} ;k okeiUFk vuqxkeh Fks Aberratio, aberration lkekU; ls fopfyr gksuk] izdk'k dh fdj.kksa dk viw.kZ viorZu] foiFku- Hkzked o vUrZxr vkjksi yxkdj iQsMjs'ku ls lEc} ftyk bdkbZ;ksa ds ofj"B buds cnys O;ogkj fy[kks Chromatic aberrationfHkUu rjax&nSè;Z dh izdk'k fdj.kksa dk ,d ySal ds }kjk vkleku inkf/dkfj;ksa dks xqejkg djus dk iz;kl fd;k tk jgk gS- okjk.klh ftyk bdkbZ uSfrdrk ls O;fHkpkj fy[kks- viorZu ftlls ,d /q¡/yk ,oa jaxhu izfrfoao curk gS] of.kZd foiFku] fopyu- us muds }kjk yxk, x, leLr vkjksiksa ij ppkZ dh vkSj bl fu"d"kZ ij igWph fgrs'k dqekj 'kekZ] fctukSj Chromosomal aberration xq.klw=kksa dh la[;k ;k muesa fLFkr inkFkZ dh vlekurk- fd Jh vxzoky iQsMjs'ku dks detksj djus ds mn~ns'; ls dqN ftys ds dkxt Distantial aberration nwj dh oLrq ns[kus esa /q¡/ykiu gksuk] nwj n`f"V fopyu] nwjh foiFku- ij fojks/h laxBu pykusokyksa ls lkWB&xkWB dj fo'kq} :i ls laxBu dks detk- Mental aberration ekufld foiFku] efLr"d ds lkekU; dk;ks± ls fopyu] ekufld fopyu- sj djus dk iz;kl dj jgs gSa- dsfeLV dh izR;sd lkykuk cSBd esa ys[kk&tks[kk cjlkrh jksxksa esa dkjxj gSa Spherical aberration fdlh xksy ySal dh izdk'k dh lHkh fdj.kksa dks ,d LFkku ij dsafnzr ikl gksrk vk;k gS] ftldh dkWih Hkh lHkh lnL;ksa dks ekSds ij ,oa Mkd&dksfj;j djus esa v{kerk] xksykdkj foiFku- }kjk Hksth Hkh tkrh jgh gS vkSj laxBu ea=kh egksn; dh Lohd`fr Hkh jgrh Fkh] gksE;ksiSfFkd nok,a ;g yksxksa dk Hkze gS fd gksE;ksiSfFkd nok,a nsj Aberrometer fopyu vFkok foiFku ekid ;a=k] fopyuekih ;a=k- vc ;g vpkud vius futh LokFkZo'k iQsMjs'ku ds ofj"B inkf/dkfj;ksa ds fo:} Abevacuation viw.kZ eyksRlxZ ;k de (dCt) gksuk- vUrZxr izyki o feF;k dj iQsMjs'ku dh Nfo dks /wfey djus dk iz;kl dj ls iQk;nk igaqpkrh gSa- blds foijhr lR;rk ;g gS fd vuqHkoh ,oa ;ksX; fpfdRld }kjk Abeyance dqN le; ds fy, fdlh fØ;k dk :d tkuk] vHkko- jgs gSa- lcls vk'p;Ztud ckr ;g gS fd iQsMjs'ku ds [kkrksa dk lapkyu dSls Abietate ,fo,fVd vEy dk yo.k- gksxk] dkSj djsxk ;g mUgs vPNh rjg ekywe gS] iQsMjs'ku dh lafo/ku dh izfr y{; lewgksa ij nh xbZ nok] jksxksa esa vU; izp- Abiogenesis thoksa dk futhZo inkFkksZ ls mRifÙk] vkthotuu- Hkh ges'kk muds ikl ekStwn jgrh gS] fyr i¼fr;ksa Abiologic vthotuu ls dksbZ laca/ u gksuk- iQsMjs'ku ds [kkrksa dk lapkyu vkbus dh dh nokvksa dh Abiology vthfor oLrqvksa dk vè;;u] vthofoKku- rjg lkiQ gS- vis{kk 'kh?kz ykHk igaqpkrh Abiosis vthork] e`R;q- vkWuykbu nokb;ksa dh fcØh gS- lkFk gh Abiotic vtho] e`r- budk nq"izHkko Abiotrophy/abiotrophia le; ls iwoZ dqN vaxksa dh thou 'kfDr de gks tkus ls mudk dk;Z dk fd;k cfg"dkj u djuk] vthohiks"k.k- u gksus dh ehfM;k gkml dks feyh tkudkjh Abirritant {kksHk 'kked] {kksHk esa vkjke igq¡pkusokyk] larkigj- otg ls ejht lfr'k diwj eksñ 09814719692 ds Abirritate {kksHk dks 'kkar djuk] mÙkstuk de djuk- 'kh?kz vkjksX; }kjk iatkc dsfeLV ,lksfl,'ku us Abirritation mÙkstukgj.k] mi'ke- dks izkIr gksrk voS/
www.medicaldarpan.com abuse," Marcus said. "That can be an unreliable measure, especially in those who drink heavily. In our study, alcohol abuse was documented in patients' medical records." He said that the study did not quantify how much alcohol patients drank. In an editorial accompanying the new study, Michael H. Criqui, of the University of California San Diego, wrote that previous studies that found a bene- fit from alcohol consumption in protecting against heart attack and congestive heart failure were so- called cohort studies, which include defined populations. Such studies tend to recruit stable, coop- erative and health-conscious participants who are more likely to be oriented toward a healthier lifestyle. "Cohort studies have minimal participation by true alcohol abusers, so the current study likely presents a more valid picture of heavy drinking outcomes," Criqui said. ^pwuk ve`r gS* blds vkS"k/h; xq.k tkudj gSjku gks tk,axs vki uke ls FkskM+k vthc yx jgk gS u dh pwuk] ;kj blds Hkh iQk;ns gS D;k\ ysfdu okLro esa blds Hkh cgqr iQk;ns gS] ge vkidks pqus ds dqN iQk;ns crk,¡xs tks vkidks gSjku dj nsaxs- pwuk ,d VqdM+k NksVs ls feV~Vh ds crZu esa Mkydj ikuh ls Hkj ns] pwuk xydj uhps vkSj ikuh Åij gksxk- ogh ,d pEep ikuh fdlh Hkh [kkus dh oLrq ds lkFk ysuk gS- 50 ds mez ds ckn dksbZ dSfY'k;e dh nok 'kjhj esa tYnh ugh ?kqyrh pwuk rqjUr ?kqy o ip tkrk gS- tSls fdlh dks ihfy;k gks tk;s ekus tkWfUMl mldh lcls vPNh nok gS pwuk xsgw¡ ds nkus ds cjkcj pwuk xUus ds jl esa feykdj fiykus ls cgqr tYnh ihfy;k Bhd dj nsrk gS- ;s gh pwuk uiqladrk dh lcls vPNh nok gS vxj fdlh ds 'kqØk.kq ugh curk mldks vxj xUus ds jl ds lkFk pwuk fiyk;k tk;s rks lky Ms<+ lky esa Hkjiqj 'kqØk.kq cuus yxsaxs] vkSj ftu ekrkvksa ds 'kjhj esa vUMs ugh curs mudh cgqr vPNh nok gS ;s pwuk- fo|kFkhZ;ksa ds fy;s pwuk cgqr vPNk gS tks yEckbZ c<+krk gS- xsgw¡ ds nkus ds cjkcj pwuk jkst ngh esa feyk ds [kkuk pkfg,] ngh ugh gS rks nky esa feyk ds [kkvks] nky ugh gS rks ikuh esa feyk ds fi;ks& blls yEckbZ c<+kus ds lkFk Lej.k 'kfDr Hkh cgqr vPNk gksrk gS- ftu cPpksa dh cqf¼ de dke djrh gS efreUn cPps mudh lcls vPNh nok gS pwuk tks cPps cqf¼ ls de gS] ftu cPpks dk fnekx nsj esa dke djrk gS] nsj esa lksprs gS gj pht mudh Lyks gS] mu lHkh cPps dks pwuk f[kykus ls vPNs gks tk;saxs- cguksa dks vius ekfld /eZ ds le; vxj dqN Hkh rdyhiQ gksrh gks rks mldk lcls vPNh nok gS pwuk- gekjs ?kj esa tks ekrk;sa gS ftudh mEkz ipkl o"kZ gks x;h vkSj mudk ekfld /eZ ca/ gqvk mudh lcls vPNh nok gS pwuk- xsgw¡ ds nkus ds cjkcj pwuk gj fnu [kkuk nky esa] yLlh esa] ugh rks ikuh eas ?kksy ds ihuk- tc dksbZ ek¡ xHkkZoLFkk esa gS rks pwuk jkst [kkuk pkfg, D;ksafd xHkZorh ek¡ dks lcls T;knk dSfY'k;e dh t:jr gksrh gS vkSj pwuk dSfY'k;e dk lcls cM+k HkUMkj gS- xHkZorh ek¡ dks pwuk f[kykuk pkfg, vukj ds jl esa vukj dk jl ,d di vkSj pwuk xsgw¡ ds nkus ds cjkcj ;s feyk ds jkst fiyk;s ukS eghus rd yxkrkj nhft;s rks pkj iQk;ns gksaxs& igyk iQk;nk%& ek¡ dks cPps ds tUe ds le; dksbZ rdyhiQ ugh gksxh vkSj ukWeZy fMfyojh gksxh] nwljk%& cPpk tks iSnk gksxk oks cgqr g"V iq"V vkSj rUnq:Lr gksxk] rhljk%& cPpk cgqr gksf'k;kj gksrk gS cgqr Intelligent vkSj Brilliant gksrk gS mldk IQ cgqr vPNk gksrk gS-] pwuk ?kqVus dk nnZ Bhd djrk gS] dej dk nnZ Bhd djrk gS] dU/s dk nnZ Bhd djrk gS] ,d [krjukd chekjh gS Spondylitis oks pwus ls Bhd gksrk gS- dbZ ckj gekjs jhM+ dh gM~Mh esa tks euds gksrs gS mles nwjh c<+ tkrh gS Gap vk tkrk gS- ;s Bhd djrk gS- mldks jhM+ dh gM~Mh dh lc chekfj;k¡ Bhd gksrh gS- vxj vkidh gM~Mh VwV tk;s rks VwVh gqbZ gM~Mh dks tksM+us dh rkdr lcls T;knk pwus esa gS- pwuk [kkb, lqcg dks [kkyh isV-] e¡qg esa BaMk xeZ ikuh yxrk gS rks pwuk [kkvks fcydqy Bhd gks tkrk gS-] eq¡g esa vxj Nkys gks x, gS rks pwus dk ikuh fi;ks rqjUr Bhd gks tkrk gS- 'kjhj esa tc [kwu de gks tk;s rks pwuk t:j ysuk pkfg,] ,uhfe;k gS [kwu dh deh gS vukj ds jl esa vukj ds jl esa pwuk fi;s [kwu cgqr c<+rk gS] cgqr tYnh [kwu curk gS ,d di vukj dk jl xsgw¡ ds nkus ds cjkcj pwuk lqcg [kkyh isV- ?kqVus esa f?klko vk x;k vkSj MkWDVj dgs ds ?kqVuk cny nks rks t:jr ugh pwuk [kkrs jfg;s vkSj gjflaxkj ds iÙks dk dk<+k [kkb;s ?kqVus cgqr vPNs dke djsaxs-
3 o"kZ rd ?kj cSBs ;g lekpkj i=k i<+us ds fy;s gekjs iatkc uS'kuy cSad ds [kkrk la[;k 1824002100120081] IFSC Code - PUNB0182400 tks fd eSMhdy niZ.k ds uke ls gS] esa :ú 250@& tek dj viuk iwjk irk gekjs iQksu uaú& 09410434811 ij SMS dj nsaA AlwaysSmile WorkMore
Biocon Biologics Symposium on ‘100 years of Insulin – Delivering on Universal Access & Equitable Care’ Resonates Well with Leading KOLs at IDF Congress 2019 Bengaluru:- Nearly a century after the discovery of insulin, millions of people with diabetes are denied access to this life-saving therapy due to its prohibitive costs. Insulin-dependent diabetes patients are not just finding it difficult to access insulin in emerging markets, even those in devel- oped markets like U.S. are finding it difficult to afford insulins therapy. Growing worldwide concern about the cost of insulin is driving the quest to find viable, long-term solutions to improve insulin access and affordability. Biocon Biologics, committed to enabling affordable access, launched its ‘Unlock Universal Access to Quality Insulins’ initiative in September 2019 with an announcement to provide recombinant human Insulin (rh-Insulin) at less than 10 US cents / day for Governments in Low and Middle-Income Countries (LMICs) at a UNAIDS Health Innovation Exchange event on the side-lines of the 74th session of the UN General Assembly in New York. Taking forward its mission to unlock affordable access to insulin, Biocon Biologics participat- ed for the first time at the IDF (International Diabetes Federation) Annual Congress, focused on ‘Shape the future of dia- betes’, which was held in Busan, South Korea f r o m December 2 to December 6, 2019. As a com- mitted global insulins player, Biocon Biologics is engaging with diverse stakeholders at various global forums to seek their partici- pation in its 10 cents mission in order to expand affordable access to rh-insulin for patients across the globe. In line with its Universal Access mis- sion, the Company organized a symposium on ‘100 years of Insulin – Delivering on Universal Access & Equitable Care’ during the IDF Congress. The Symposium was opened by Mr Satish Sivan, the Deputy Chief of Mission, Embassy of India in Korea, who appreciated the efforts being made by Biocon Biologics to unlock afford- able access to insulins for patients across the globe. “India has been rightly called the pharmacy capital of the world with consis- tent track record in producing high quality affordable pharmaceutical products with advances in Biological therapeutics. India has seen companies like Biocon become world leaders in developing Biosimilar therapeutic entities especially for diabetes and cancer,” he said. The Symposium was addressed by Dr Andrew Boulton, Professor at Manchester University and President, IDF, Dr Radhakrisha Sothiratnam, consultant physician, Columbia Asia Hospital, Seremban, Malaysia, Dr Irl Hirsch, Professor of Metabolism, Endocrinology and 2 Nutrition, University of Washington, U.S., Renza Scibilia, Manager- Type 1 Diabetes and con- sumer Voice, Diabetes Australia. “Is diabetes the cancer of the 21st century? Neither malaria nor AIDS, but diabetes is the biggest health challenge today. Explosion of diabetes in Asia is resulting in a rising global public tsunami. A 150% rise in type 2 diabetes in South Asia from 2000 to 2035, has been estimated. Lack of equitable access to affordable insulin remains a key impediment to successful treatment and results in co-mor- bid complications and premature deaths. In developed markets too, thousands of people are finding it difficult to afford expen- sive insulins therapy. To tackle this huge economic burden that diabetes poses, gov- ernments across the world need to ensure that they have a universal health coverage system, which includes insulin and dia- betes care,” said Dr Andrew Boulton, Professor at Manchester University and President, IDF. “Our symposium at IDF Congress brought together leading KOLs from across the globe to seek viable, long-term solutions to improve insulin access and affordability. The discussions pointed towards diabetes being a universal challenge for patients not just in LMICs but also in devel- oped markets like the U.S., where patients outside the health security net are forced to ration insulins due to its high cost. We believe Biocon Biologics along with other stakeholders including like- minded insulins providers can enable equitable access to insulins for patients globally,” said Christiane Hamacher, CEO, Biocon Biologics. Speaking on ‘Validated Biosimilar insulin: A Journey from clinical trials to real world evidences’, Dr Radhakrisha Sothiratnam, consultant physician, Columbia Asia Hospital, Seremban, Malaysia, said, “Governments should encourage the use of biosimilar insulins which being afford- able provide governments, healthcare profes- sionals and patients the opportunity to lower healthcare costs. Biocon has been able to increase access to insulins in Malaysia by introducing affordable therapeutic options through its locally produced recombinant human insulin and Insulin Glargine. Going for- ward, the export of affordable insulin therapies from Malaysia to the rest of the world will help bring smarter solutions for a healthi- er life to patients and customers in the neighboring countries.” Appreciating Biocon Biologics’ initiative to enable universal access to insulin globally, Dr Sothiratnam added, “The 10 cents Mission makes pure sense now, when universal access to insulin still remains a distant dream.” In his address on ‘Insulin Pricing and Barriers to Access: the US Perspective for Improved Outcomes’, Dr Irl Hirsch, Professor of Metabolism, Endocrinology and Nutrition, University of Washington, U.S., said, “Rationing of Insulin in the U.S. is twice as compared to any LMICs, with 26% Americans rationing this because of the costs. The health care system is currently broken in the U.S., with prices of insulin being tripled between 2002 and 2013, leading to one out of four Americans rationing their insulins. Till date, there has not been a solution for adequate access for all Americans to obtain insulin. There is hope, however, that within the next year we will have our first biosimilar insulin. We believe the introduction of biosimilar insulins will generate competition in the U.S. market, bringing down prices of insulins and making high quality insulins more accessible for patients in need.” 3 Renza Scibilia, Manager- Type 1 Diabetes and consumer Voice, Diabetes Australia, in her address, spoke on how diabetic patients can improve their quality of life through proper understanding of the disease from the perspectives of a caregiver, patient advocate, dietician etc. Biocon Biologics used the IDF congress as a platform to engage with Key Opinion Leaders (KOLs), including physicians, scientists, educators, healthcare professionals, government representatives, policy makers, and IDF members to take forward its 10 cents mission to unlock affordable access to insulin. The WHO’s announcement regarding the insulin prequalification pilot program for LMICs on November 13, is well timed. Biocon Biologics welcomes this first-ever insulin prequalification program of WHO which we believe will enable access by increasing the flow of quality-assured products on the international market, providing countries with greater choice and patients with lower prices. Biocon Biologics is willing to work with governments to ensure ways to overcome price barriers, including special pricing and setting up low-cost manufacturing facilities via pub- licprivate partnerships. The Company also seeks to work with healthcare systems and payers worldwide to ensure that insulin pricing is not a constraint to the well- being of individuals and of communities. Despite the capital-intensive nature of insulin production, Biocon Biologics has succeeded in expanding access to insulin therapy in India and key global markets by pur- suing an innovation strategy that is rooted in affordabil- ity. Biocon Biologics has one of the largest insulin man- ufacturing capacities in the world, which it is using to shift the access paradigm for insulin worldwide. It has cumulatively supplied over 2 billion doses of biosimilar insulins so far to patients globally over the last 15 years. In multiple countries like Mexico and Malaysia, most of the insulin-requiring diabetics take Biocon Biologics’ insulins. The Company’s biosimilar insulins are also making a difference to people with diabetes in developed markets like EU, Japan and Australia. The Company’s rh-Insulin has been approved in over 40 countries and commercialized in countries like India, Mexico and Malaysia, while Insulin Glargine has been approved in over 60 markets and commercialized in countries like India, Australia, EU, Japan, UAE, South Korea, Mexico and Malaysia. Ph.:- 080-28082808.
uh: xxZ Lokeh dh vksj ls czts'k dqekj xxZ }kjk izdkf'kr] czts'k dqekj xxZ }kjk eqfnzr rFkk bEizs'kal fizafVax ,.M iSfdax fyfefVM uks,Mk] xkSre cq¼ uxj esa eqfnzr ,oa dsú ihú jksM] cqyUn'kgj ls izdkf'kr] lEiknd & czts'k dqekj xxZ / u vi uk ]
ij k;k u g h a ns [ krk
vuqHkoh fo'ks"kKksa ls ijke'kZ oS'kkyh (fnYyh) fLFkr eSDl vLirky ds dSalj jksx fo'ks"kK MkWñ fodkl xksLokeh izR;sd eghus ds igys vkSj rhljs cq/okj o nwljs vkSj pkSFks cq/okj dks isV vkSj yhoj jksx fo'ks"kK MkWñ vk'kh"k xxZ vkSj gM~Mh jksx fo'ks"kK MkWñ fudqat vxzoky izR;sd eghus ds nwljs vkSj pkSFks ohjokj dks vkstl vkbZ ds;j vLirky cqyUn'kgj esa viuh lsok,a nsaxs- eksñ 8979415070] 9219414085- u'khyh xksfy;k¡ o dSI'kwy ds lkFk rhu ncksps fiQYykSj% iatkc ds fiQYykSj iqfyl dks feyh cM+h dke;kch gtkjksa u'khyh xksfy;ka o dSIlwy ds lkFk rhu idM+s- ,l-,p-vks- lqD[kk flag us crk;k ,d dM+h e'kDdr ds lkFk bu rhuksa idM+ fy;k x;k gSa- igys dsl esa fiQYykSj iqfyl us xqy'ku dqekj oklh 'kkgdksV dks 20]000 u'khyh xksfy;ka lesr fxjÝrkj dj fy;k x;k gSa- nwljs dsl esa iqfyl us ijfeUnz flag oklh iykgh Fkkuk iQxokM+k dks 1080 xksfy;ka ds lkFk /j nckspk- blh izdkj iqfyl us iznhi flag oklh mPpk xkao Fkkuk irkjk dks 1200 ls vf/d u'khyh xksfy;ka o dSIlwy ds lkFk idM+k gSa- iqfyl us rhuksa vkjksfi;ksa dks dksVZ esa is'k dj fn;k gS o mlls vkxs iwNrkN tkjh dh fd ;s xksfy;ka o dSIlwy dgka tkdj csprs gSa- www.medicaldarpan.com
uh: xxZ Lokeh dh vksj ls czts'k dqekj xxZ }kjk izdkf'kr] czts'k dqekj xxZ }kjk eqfnzr rFkk bEizs'kal fizafVax ,.M iSfdax fyfefVM uks,Mk] xkSre cq¼ uxj esa eqfnzr ,oa dsú ihú jksM] cqyUn'kgj ls izdkf'kr] lEiknd & czts'k dqekj xxZ